AACR Bulletin Board

Institution of Page Charges
Effective January 1, 1997, a page charge of $35 per printed page will be levied on all manuscripts published in Clinical Cancer Research. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Fotti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Annual Meeting
The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in San Diego, CA, April 12–16, 1997. The Chairperson of the Annual Meeting is Frederick P. Li of the Dana-Farber Cancer Institute. Clara Derber Bloomfield of the Roswell Park Memorial Institute and Stephen H. Friend of the Fred Hutchinson Cancer Research Center will serve as Co-Chairpersons. The Program Committee has invited outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They are also now reviewing the proffered papers submitted by members of the cancer research community. The deadline for abstract submissions was November 12, 1996. Up-to-date program information can be obtained via the Internet at the AACR’s website (http://www.aacr.org/meetings.html).

Gertrude Elion Cancer Research Award
Applications for the AACR’s 1997 Gertrude Elion Cancer Research Award, supported by an educational grant from Glaxo Wellcome Oncology, are due February 14, 1997. The one-year, $30,000 grant to a nontenured Assistant Professor supports meritorious basic, clinical, or translational research in cancer causation, prevention, or treatment. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. Information and application forms were mailed to AACR members and to those who requested applications. Nonmembers should request information and applications from the AACR office.

AACR Research Fellowships
This year the AACR will offer at least six one-year, $30,000 research fellowships for clinical or postdoctoral fellows working in the U.S. or Canada. Information and a universal application form will be mailed to all AACR Members in these countries and to others upon request for any of the following: the Research Fellowship in Clinical Research, sponsored by Bristol-Myers Squibb; the Research Fellowship in Clinical/Translational Research, sponsored by Amgen; the Research Fellowship in Prevention, sponsored by the Cancer Research Foundation of America; and three Research Fellowships in Basic Research, sponsored by The Sidney Kimmel Foundation for Cancer Research, Hочest Marion Roussel, and the AACR. Additional fellowships and sponsors may be announced. To be eligible for these fellowships, candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. The deadline for applications for the research fellowships is Friday, February 14, 1997.

AACR Special Conferences in Cancer Research
A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for some of these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. FAX: (215) 440-9313. E-Mail: aacr@aacr.org. Up-to-date program information is available via the Internet from the AACR’s website (http://www.aacr.org/confmc.html).

January 10–14, 1997
Basic and Clinical Aspects of Lymphoma
Joint Meeting with the American Society of Clinical Oncology
Chairpersons:
JOSEPH R. BERTINO, New York, NY
JAMES O. ARMITAGE, Omaha, NE
Stouffer Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

March 7–12, 1997
Basic and Clinical Aspects of Breast Cancer
Chairpersons:
J. CARL BARRETT, Research Triangle Park, NC
KAREN S. H. ANTMAN, New York, NY
MARY-CLAIRE KING, Seattle, WA
Keystone Resort, Keystone, CO

June 7–11, 1997
Cancer of the Central Nervous System
Conference with Neurosurgery Joint Section on Tumors
Chairpersons:
PETER McL. BLACK, Boston, MA
WEBSTER K. CAVENEE, La Jolla, CA
Loews Coronado Bay Resort, San Diego, CA
Acknowledgment to Reviewers

The Editor-in-Chief, the Associate Editors, and the Editorial Advisory Board acknowledge with appreciation the assistance of the following individuals who have generously contributed their time and effort during the past year* to review manuscripts for Clinical Cancer Research. The quality of the journal can be attributed in large measure to the quality of their effort, for which we are sincerely grateful.

A
Stuart A. Aaronson
Reed Adams
G. Adema
Carol Aghajanian
David Agus
Mark Albertini
Francis Ali-Osman
Suresh Ambudkar
Kenneth Anderson
Marshall W. Anderson
Paul Anderson
Kian Ang
Jack I. Arbiser
Susan G. Arbuck
Ralph B. Arlinghaus
Carlos Arteaga
Vasilios Assikis
Michael B. Atkins

B
Debabrata Banerjee
Menashe Bar-Eli
Richard Bartakat
Lini Bartlett-Pandite
Jose Baselga
Susan Bates
Atul Bedi
Dorthea Bekker
William Bellamy
William Bennett
Christopher Benz
Andrew Berchuck
Michael Berens
Nathan Berger
Ira Bergman
Nancy Berliner
Ralph Bernacki
Donald Berry
Joseph Bertino
Kapil N. Bhalla
Jaclyn Biegel
Darrel D. Bigner
Archie Bleyer
Carl Blomqvist
Arthur W. Boddie, Jr.
Michael Bookman
Anne-Lise Borresen
Piet Borst
Jeffrey Boyd
Glen Branoff
Michael G. Brattain
Eric Bremer
Dean E. Bremer

C
Vli Brinkeman
Jim Brooks
Barry Brown
Carol Brown
Powel Brown
Hal E. Broxmeyer
H. Broxterman
Corazon Bacana
Donald Buchsbaum
Paul Bunn
Antonio Buzaid

D
Paul Cairns
Mitchell Cairo
Michael Caligiuri
Lisa Cannon-Albright
Giovanni Capranico
David Carbone
Michael Carducci
Ashele Carlo
Jorge Carrasquillo
W. E. Carson
Ronald Cartenhaus
Terrence Cascino
Doug Case
Diana Casper
Raju Chaganti
Richard Champlin
Paul Chapman
Martin Cheever
Luci Chen
Yung-Chi Cheng
Bruce D. Cheson
Jia Lin Chou
Randolph Christen
Kathy Christman
Gary M. Clark
Pinchas Cohen
Daniel Coit
Thomas H. Corbett
C. Cordon-Cardo
Joseph M. Corey
Marion Couch
Patrick J. Creaven
S. P. Creekmore
R. Crystal
Kevin Cullen
David Cunningham
Brendan Curti
John P. Curtin

E
Robert Damato
Peter Danenberg
Mary K. Danks
Ian David
Andre Davidoff
Nancy Davidson
Lisa M. Deangelis
A. De La Chapelle
George D. Demetri
Samuel Dermeale
Beth Deutch
Russell Devore
G. E. De Vries
Theodore Deweese
Daniel Dexter
Kapil Dhirunga
Alan M. Diamond
Chaitanya R. Divgi
Ethan Dmitrovsky
Lawrence A. Donehower
M. Dowsett
Glenn Dronoff
Anatoly Dritschilo

F
Janet Earyl
Gail Eckhardt
Stephen Egde
Janine Einspsahr
Elizabeth A. Eisenhauer
Wafik S. El-Deiry
Richard Ellledge
Matthew Ellis
Mike Emmertbuck
Adel K. El-Naggar
Ethel Estey
Sharon Evans

G
Janice Gabrilove
John Galivan
Gary Gallick
Steven Gallinger
Varsha Gandhi
Giampietro Gasparini
Adi F. Gazdar
Akihiko Gemma
Robert Gemmill
Eugene W. Gerner
Stanton L. Gerson
Alan Gerwitz
Maria-Ama Ghetie
Cecilia M. Gueblli
Terri Gilewski
Stephen Gillies
Claude Gimmi
Beppin Giovannella
Ruth A. Gjeset
Eli Glatstein
Bonnie Glisson
David Goldenberg
Jared Gollob
Michael Gordon
Michael Gottsmann
Michael Gould
Kenneth Grabstein
Stephen Graziano
Anthony Greco
Mark Green
Jean Gren
Liam Grogan
Michael Grossbard
H. Bartong Grossman
Stephen Gruber
F. Peter Guengerich
Jose G. Guillem
Elora Gupta
Hiral L. Gurtoo
Gordon Gutterman

*October 1, 1995 - September 30, 1996.
Acknowledgment

John James Thomas
Abbruzzesel
Crystal Jacob
Malik
Joseph
Michael
Gerrit
Patrick
Paul
Clifford
Robert
William
Alan
David
Gabriel
Jeff
James
M.
Harald
Steadman
Howard
Ruth
Peter
Frederic
Hagop
Burton
David
Suresh
Robert
Ann
Steven
Meenhard
Holt
L.
Hutson
Hausdorff
Halaban
Houghton
Huang
Hafkmeyer
Isra
Kagan
Karr
Joseph
Juric
Malik
Juweid
Jacob Kagan
Burton A. Kamen
Crystal Kaner
Hagop Kantarjian
James P. Karr
Seymour Kauffman
Frederic J. Kaye
Abbruzzesel Khuri
Fadi Khuri
Gretchen Kimmick
Hedy Lee Kindler
Kenneth Kinzler
E. S. Kleiman
Hynda K. Kleinman
David Knowles
Maggie Knowles
Susan J. Knox
Wayne Koch
Elise C. Kohn
Kristin Komschlies
Steven Korsblau
Robert Kreitman
Mark G. Kriv
Davud Krizman
Susan Krown
Athanassios P. Kryitsis
John G. Kuhn
Rakesh Kumar
Jonathan Kurie
John F. Kuttesch, Jr.
Steven Larson
Julia Lawrence
J. Jack Lee
Jin Soo Lee
Mong Hong Lee
Sam W. Lee
Catherine Leitch
Heinz-Josef Lenz
Ellis Levine
Frank Lieberman
Eugene W. Linger
Ilona Linnoila
Martin Lipkin
Scott Lippman
Alan List
Virginia A. Livolsi
Charles Loprinzi
Gerrit Los
Reuben Lotan
Scott Lowe
Greg Macewen
Bruce Mackay
Timothy Madden
David Mahvi
Louis Malaspes
Daniel C. Maneval
Sridhar Mani
A. Mantovani
Li Mao
Sanford Markowitz
Mary Beth Martin
M. Jules Mattes
Helena Maurer
John D. McConnell
Timothy J. McDonnell
Cornelius McGinn
Robert J. Melder
Stephen J. Meltzer
Neal J. Meropol
Edward M. Messing
Joseph Michaeli
James Mier
Tom Mikkelsen
Gerard Milano
Langdon Miller
Wilson Miller
Gordon Mills
Sin Mineishi
James B. Mitchell
Margalit Mokyr
T. Monig
Terry W. Moody
M. J. Moore
Malcolm A. S. Moore
Richard Moran
Joanne Mortimer
Robert Motzer
Elaine A. Muchmore
Franco Muggia
Carolyn Muller
Sharon Murphy
James Lee Murray
Ruth Muschell
Jeffrey Myers
David Nanus
Alfred Neugut
Stephen Nimer
Perry Nisen
John L. Nittis
James C. Norton
Gabriel Nunez
Augusto C. Ochoa
P. M. O’Connor
Peter J. O’Dwyer
Paul Okunieff
Susan Ostrad-Rosenberg
Paola A. Paciucci
R. Packer
David L. Page
Lance C. Pagliaro
Ramon Parsons
Jens Pedersen-Bjergaard
Anthone E. Pegg
Roman Perez-Soler
James J. Perry
Godefridus J. Peters
Elizabeth M. Petty
David Pfister
James Phan
Steven Plantadosi
Gary Piazza
Kenneth J. Pienta
Stefano Pileri
Silvana Pilotti
Renate Pitz
David Piwnia-Worms
William K. Plunkett
Ian Pollack
Michael N. Pollack
Bruce Polsky
Yves Pommier
Curt Porter
Carol Portlock
William Powell
E. A. Poynor
Michael Prados
Harvey Priesler
Robert Radinsky
A. Rameswamy
Timothy Rebeck
Eddie Reed
Ralph A. Reinfeld
Elizabeth Repasky
Leonard Reino
Daniel Rifkin
Jenne Rizzo
Anita Roberts
Michael Robertson
James Rocco
William Rose
Neal Rosen
Maury Rosenstein
Miriam Rosin
Marsha Rosner
Eric Rowinsky
Eric H. Rubin
Stephen Rubin
Jeffrey Rubnitz
Valerie W. Rusch
Youcef Rustum
Michael Sadelain
Nagahiro Sajo
David Salomon
Leonard B. Saltz
Michael K. Samoszuk
Leona D. Samson
D. S. R. Sarma
Stimson Schantz
David Scheinberg
Russell J. Schilder
Christine Schold
S. Clifford Schold, Jr.
Jan H. Schornagel
Gary Schwartz
Sidney A. Scudder
Andrew Seidman
Yoshitaka Sekido
D. Sewell
Jatin P. Shah
Kevin Shannon
Fred Shapiro
William Shapiro
Robert Sharkey
Thomas C. Shea
Darryl Shibata
Moshe Shike
Dong M. Shin
Tzipora Shoshani
Clay B. Siegall
Branimir I. Sikic
Lewis M. Slater
Kendall Smith
Martin Smith
Mitchell R. Smith
Thomas J. Smith
Harriet O. Smitt
Mark Sobel
A. Sobrero
Mel Sorensen
Lee Paijeff Sosman
Thierry Soussi
Lisa Speicher
Richard Spencer
Margaret Spitz
Michael B. Sporn
George F. Springer
William Stetler-Stevenson
R. G. Stoller
Walter Storkus
Yan Su
Saraswati Sukamar
Walter J. Urba

R
Raymond Taetle
Michael A. Tainsky
Chris H. Takimoto
Hiroshi Takita
Moshe Talpaz
Rajeshwar Rao Tekmel
Nitin Telang
Franz Thiebaut
John Thompson
Joyce Thompson
Timothy Thompson
Snorri Thorgeirsson
Philip E. Thorpe
Linda Titus-Ernstoff
Debra A. Tonetti
Giampaolo Tortora
Anthony Triston
Dean Troyer
Donald Trump
Robert Tucker
Eva Turley

T
Juan Carlos Vera
Jacob Verweij
Ellen S. Vitetta
Cathy D. Vocke
E. E. Voest
Nicholas Vogelzang
Everett Vokes
Israel Voldavsky

U

W

V

W

W

W

W

V

V

V

V

V

V

V

V

V

V

V

V

V

V

Walter J. Urba

Steven D. Weitman
Anton Wellstein
Sidney Welt
Harold Werbin
Max Wicha
George Wilding
S. Williams
Mark C. Willingham
C. Roland Wolf
Renella Wolf
Eugene A. Wolterine

Joachim Yahalom
Alan M. Yahanda
David Yandell
Samuel Yeh
Charles Young
Garret Yount
W. K. Alfred Yung

Daniel Zelterman
Wei Zhang
Karen Zier


SUBJECT INDEX

Volume 2

prostatic hyperplasia and carcinoma, 889

Aneuploidy
breast carcinoma, 883

Aneuropathy
breast carcinoma, 883

Antibody: see also Monoclonal antibody

Antikinase
expression, pancreatic carcinoma, 1607

Antigen
expressing cells
TNF-B(Fv) fusion protein cytotoxic antitumor activity, 1523
HLA-A1
melanoma T-cell epitopes, detection, 87
HLA-A2
melanoma loss, 641
proliferating cellular nuclear and occult neck metastases, laryngeal carcinoma, 1801
truncated p21 adenovirus, growth suppression, 1221
prostate-specific -producing prostatic carcinoma xenograft LuCaP 23, 1039
prostate-specific membrane
folate hydrolyse, prostatic carcinoma cells, 1445
transporters associated with processing MHC class I and, renal cell carcinoma, 1427
tumor
gene expression, gastric carcinoma, 1619

Antisense oligonucleotides
anti-EGF-related growth factor
growth inhibition, colon carcinoma, 601
c-myc blockade, thyroid carcinogenesis, 119

Apoptosis
and chemosensitivity, tumor cells, 623
colorectal tumorigenesis, 1999
induction
ATRA and 4HPR, head and neck squamous cell carcinoma cell lines, 855
ceramide and, 1
phenylbutyrate, prostate cancer, 379
loss, duodenal breast carcinoma, 1887
modulation by HER2 overexpression,
MCF-7 cells, 1215
modulation by PKC signal transduction pathway, 1915

AR209
effects on orthotopic human lung cancer, 1851

Arabinosylcytosine: see Cytarabine

Area under the concentration-time curve
total topotecan, limited sampling model, 43

Aromatic fatty acids
multidrug resistance vulnerability, 865

ATRA: see all-trans-Retinoic acid

AUC curve: see Area under the concentration-time curve

Autologous tumor cell vaccine
Newcastle disease virus-infected active specific immunotherapy, colorectal carcinoma, 21

Auto transplants
high-dose melphalan, renal failure, 947

Auxiliary lymph nodes
-negative breast cancer
hs27, 1199
Ki-67 vs S-phase fraction, 585

B

BAGE
expression, gastric carcinoma, 1619

Batimastat
growth inhibition, solid breast tumors, 1207

BB-94: see Batimastat

B cells
chronic lymphocytic leukemia
chromosome 13q14 deletions, 1673
lymphoma
recurrent, **Y-labeled anti-CD20 mAb therapy, 457
precursor, leukemia
B43-PAP plus cytosine arabinoside treatment, SCID mice, 1533

bc1-2 protein
expression
non-small cell lung cancer, 915
prostatic cancer, 389
reseetable pancreatic adenocarcinoma, 2015
T, breast cancer, 1887

-beta induced apoptosis
modulation by HER2 overexpression, MCF-7 cells, 1215
prognostic significance

Acrolein
multidrug resistance protein modification, 1321

Adenocarcinoma, colon
irinotecan combined with 5-fluorouracil or etoposide, xenograft models, 107

Adenocarcinoma, pancreatic resectable
bcl-2 and p53 expression, 2015

Adenovirus
p21
truncated, growth suppression, 1221
wild-type p53, radiation sensitization, 1665

Adhesion molecules
CD8 T cells
GM-CSF release, melanoma T-cell epitope detection and, 87
CD20
**Y-labeled anti-CD20 mAb, recurrent B-cell lymphoma therapy, 457
CD44
expression, pancreatic carcinoma, 1607
mRNA isoforms, thyroid and breast carcinoma, 1251
variant isoforms, malignant melanoma, 447
expression, lymphoma liver metastasis, 811

5'-AdThd: see 5'-Amino-5'-deoxythymidine

Aerosol delivery
interleukin 2 liposomes, canine studies, 721
natural IL-2, pulmonary malignancy, 1115

AG331
continuous infusion, phase I trial, 1685

6-O-Alkyguanine-DNA alkyltransferase
modulation by carmustine and streptozocin, refractory melanoma, 1129

Alkytransferase
quantitative immunohistochemistry.
malignant colon, 577
retroviral gene transfer, human hematopoietic progenitors, 1353

ALRT1057
combined with cisplatin antitumor effects, human oral squamous carcinoma xenografts, 511

9-Aminocamptothecin
cisplatin cytotoxicity potentiation, 687

5'-Amino-5'-deoxythymidine
IdUrd metabolism modulation, colon cancer xenografts, 981

Aminopterin
leukemia treatment, 69
Androgen
receptors
gene mutations, prostate cancer, 277
Subject

BCNU: see Carmustine

BEC2

anti-idiotypic vaccine

immunization, melanoma, 679

Bile

irinotecan metabolites, 1943

Bioassay

P-glycoprotein inhibition, serum, 403

Biological agents

metastatic melanoma, phase I study, 295

Biomarkers

p53 mutations, multifocal transitional cell carcinoma of bladder, 1795

Bisantrene

hematoxicity

bisantrene resistance, retroviral MDR1 gene transfer, 973

Bizelesin

antitumor activity, mice, 1143

Bladder carcinoma

chemotherapy

bifunctional anthracycline and nitrosourea, 1315

p53 mutations, 1055
telomerase activity, 929

transitional cell

multifocal, molecular screening with p53 mutations, 1795

Bladder tumors
doxorubicin pharmacodynamics, 1275

Bladder washings

p53 mutations analysis, 1055

Bleomycin

resistance
cytokeratin expression and, 97

Blood: see Peripheral blood; Whole blood

Blood vessels
tumor

counts, intestinal-type gastric cancer, 1679

eosinophil peroxidase, 1867

Bone marrow

bisantrene resistance, retroviral MDR1 gene transfer, 973

B43-PAP

combined with cytosine arabinoside, B-cell precursor leukemia, 1533

Brain tumors

methylator resistance

MGMT and, 735

resection cavities with subarachnoid communication

intrathecal 131I-labeled 81C6 mAb therapy, phase I trial, 963

Breast

epithelial cells

lymphokine-activated killing

sensitivity, 207

proliferative disease

vascularity, 1873

Breast carcinoma

aneuploidy, 883

apoptosis modulation by HER2 overexpression, 1215

bilateral, clonal analysis, 743

CD44 mRNA isoforms, 1251

cell death

paclitaxel-induced, 847

chromosome 6q loss of heterozygosity, 1601

cyclin D1 and estrogen receptor mRNA levels, 923

DNA/RNA content, flow cytometric analysis, 419

ductal

apoptosis loss, 1887

estrogen receptor status

FES-PET and, 933

mRNA levels, 923

immunomagnetic purging from peripheral blood progenitor cells, 81

immunotherapy

active, gene modification of tumor cells, 59

interleukin 6 paracrine growth factor, 215

keratin 18 protein expression, 1879

MRP and MDR1 expression, 1231

node-negative

hs27, 1199

Ki-67 vs S-phase fraction, 585

p53 expression, prognostic value, 2007

node-positive

adjuvant tamoxifen, predictors of outcome, 1191

treatment failure, Her2/neu overexpression, 1509

omega-3 fatty acid suppressive effects, 1751

p16INK4a expression, 1993

p53 expression, validation, 2007

PARP expression and genomic instability, 1163

PDGF-B receptor, 773

positron emission tomography, 933

postmenopausal plasma estrogen and megestrol acetate, 1515

prognostic markers
cathepsin D, 613

cyclin D1 gene amplification, 1177

Ki-67 vs S-phase fraction, 585

MIB-1 tumor cell proliferation rate, 147

ornithine decarboxylase, 1901

p21 expression, 1591

p53 expression, validation, 2007

urokinase plasminogen activator, 613

RNA content, biological significance, 419

systemic therapy response, PET and, 933

T1

lymph node metastases, 1887

TGF-β secretion

stimulation by TNF-α, 827

treatment failure

Her2/neu overexpression, 1509

Breast carcinoma in situ

preinvasive vascularity, 1873

Breast tumors

ER and PR gene methylation, 805

growth inhibition by batimastat, mice, 1207

Bronchial epithelium

metaplastic

EGF expression, 1787

d1-Buthionine-(S,R)-sulfoximine

and multidrug resistance protein function, 1961

C

E-Cadherin

and occult neck metastases, laryngeal carcinoma, 1801

Cancer: see Carcinoma

Canthaxanthin

plasma levels, cervical intraepithelial neoplasia and cancer, 181

Carboplatin

combined with cyclosporine A

refractory gynecologic cancer, phase I trial, 1699

refractory ovarian and fallopian tube cancer, phase II trial, 1693

combined with paclitaxel, pharmacokinetics, 549

platinum-DNA adducts, IPC-MS quantitation in peripheral blood leukocytes, 1829

Carcinoma

advanced

combined leucovorin-fluorouracil and iododeoxyuridine, 1475

high-dose edatrexate with oral leucovorin, phase I trial, 1819

PALA combined with fluorouracil and dipyridamole, phase I study, 1107

9-cis retinoic acid, phase I trial, 471

choriocarcinoma

telomerase activity, 2023

cisplatin resistance

thioredoxin, 427

interleukin 1 receptor antagonist

induction after IL-1 therapy, 501

lovastatin, phase I study, 483

metastatic

interleukin-2 effects on natural killer cells, 493

serum anti-p53 antibodies predating, 1767

Te activity, mitochondria, 1335

TNF-B1(Fv) fusion protein antitumor activity, 1523

Carcinoma, bladder

chemotherapy

bifunctional anthracycline and nitrosourea, 1315

p53 mutations, 1055

telomerase activity, 929

Carcinoma, breast

aneuploidy, 883

apoptosis modulation by HER2 overexpression, 1215

bilateral, clonal analysis, 743

CD44 mRNA isoforms, 1251

cell death

paclitaxel-induced, 847

chromosome 6q loss of heterozygosity, 1601
Carcinoma, cisplatin adjuvant telomerase treatment PDGF43 cyclin node-negative interleukin immunomagnetic DNA/RNA phase stimulation ornithine plasma overexpression, cells, adjuvant hsp27, expression, expression, and expression, levels, and content, proliferation rate, and growth fraction. Carcinoma, platinum-DNA detection, angiogenesis. expression, cyclosporine and docetaxel, gene expression, wild-type and wild-type expression, of 601 therapy cytotoxicity, potentiation by wild-type p53, 1649 wild-type p53 dominance, 1639 xenografts 5'-AdTbd modulation of IdUrd metabolism, 981 Carcinoma, colorectal c-myc overexpression, 1049 immunotherapy active specific, Newcastle disease virus-infected autologous tumor cell vaccine, 21 metastases dual antibody therapy with interferon, 1811 liver, c-src and c-yes activation, 1397 p53 point mutations, 1049 radiosensitization by adenovirus wild-type p53, 1665 radiosensitization by 5-fluorouracil, 53 Carcinoma, ductal breast apoptosis loss, 1887 Carcinoma, endometrial abnormal glycolipid expression, quantitative assay, 749 and tamoxifen, 223 telomerase activity, 2023 tumor blood vessel markers eosinophil peroxidase, 1867 Carcinoma, epithelial ovarian doxetaxel, phase II study, 837 Carcinoma, fallopian tube refractory carboplatin combined with cyclosporine A, phase II trial, 1693 refractory advanced doxetaxel, phase II study, 837 signal transduction defects, tumor-associated lymphocytes, 161 telomerase activity, 2023 tumor blood vessel markers eosinophil peroxidase, 1867 variant and wild-type estrogen receptors, 2029 Carcinoma, pancreatic hyaluron receptors expression, 1607 Carcinoma, prostatic androgen and glucocorticoid receptors, 889 apoptosis phenylbutyrate induction, 379 AR gene mutations, 277 bcl-2 protein expression, 389 chromosomal aneusomies, prognostic value, 137 clustered p53 immunostaining, 399 hormone-refractory uY-CYT-356 treatment, 1289 metastatic variants, orthotopic implantation in nude mice, 1627 progression trisomy 7 marker, 1553 prostate-specific membrane antigen folate hydrodase, 1445 TGF-β1 receptor expression, 1255 TGFBR-II levels, 635
xenografts
LuCaP 23, characterization, 1039

Carcinoma, renal
local tumor irradiation combined with IL-2 therapy, murine, 1543

Carcinoma, renal cell
IL-13 antitumor effects, 1743
MHC class I, LMP, and TAP genes, 1427
13-cis-retinoic acid antiproliferative effects, 1077
retninoic acid receptor β expression, 1077

Carcinoma, small cell lung
Gemcitabine pharmacokinetics and metabolism, 359
second lung cancer, genetic analysis, 1103

Carcinoma, squamous cell
cervical
paclitaxel activity, 1285
esophageal
cyclin A overexpression, 1781
cyclin D1 gene amplification, TNM- Gene, 1155
EGFR gene amplification, 909
head and neck
antitumor effects of cisplatin combined with ALR1057, human xenografts, 511
apoptosis by ATRA and 4HPR, 855
cytotoxic therapy, tumor cell proliferation, 1453
growth stimulation by interleukin 4, 127
human papilloma virus and p53, 755
microsatellite alterations at lp loci, 903
radiotherapy, bcl-2 protein and prognostic significance after, 261
recurring, p53 mutations, 1577
topical gene therapy, organotypic model, 1659
laryngeal
cyclin D1 gene amplification, 175
lung
131I-labeled EGF radiolocalization, 13
thrombomodulin, prognostic value, 763
oral
antitumor effects of cisplatin combined with ALR1057, human xenografts, 511

Carcinoma, thyroid
CD44 mRNA isoforms, 1251
c-myc overexpression, 119
M, 67,000 expression, 1777

Carcinoma, transitional cell
bladder
multifocal, molecular screening with p53 mutations, 1795
p53 mutations and, 1055
reurrence
detection, clonality and, 1795

Carcinoma in situ, breast
preinvasive vascularity, 1873

Carmustine
combined with streptozocin, refractory melanoma, 1129

β-Carotene
plasma levels, cervical intraepithelial neoplasia and cancer, 181

Carpotezole
phase I clinical and pharmacokinetic study, 1717

Cathepsin B
malignant lung tissue, 561
prognostic significance, breast cancer, 613

Cathepsin D
malignant lung tissue, 561
prognostic significance, breast cancer, 613

Cathepsin L
malignant lung tissue, 561
prognostic significance, breast cancer, 613

CD3
peripheral blood lymphocyte expression, cervical cancer, 1825

CD8
T cells
GM-CSF release, melanoma T-cell epitope detection and, 87

CD20
anti-CD20 mAb
*Y-labeled, recurrent B-cell lymphoma therapy, 457

CD44
expression, pancreatic carcinoma, 1607
mRNA isoforms, thyroid and breast carcinoma, 1251
variant isoforms, malignant melanoma, 447

Cell cycle
G2 checkpoint
inhibitor UCN-01, cisplatin cytotoxicity and, 791

Cell death: see also Apoptosis
ceramide and, 1
trans-retinoic acid-enhanced modulation by growth factors, ovarian cancer, 1307
HSV-TK DNA and ganciclovir, 47
p53 protein, 435
programmed
paclitaxel-induced, MDA-MG-468 cells, 447
polyamine analogue-induced, lung tumor cells, 441
all-trans retinoic acid and antireceptor antibodies and, myeloma, 253

Cell growth
all-trans retinoic acid and antireceptor antibodies and, myeloma, 253

Cell proliferation
cytotoxic therapy, head and neck tumors, 1453
prognostic significance, breast carcinoma, 147

Cells
-mediated immunity
lymphocytes, 785
p53 protein, 435

Ceramide
and apoptosis induction, 1

c-erb-B2
anti-erbB-2 oncotoxin, orthotopic human lung cancer, 1851
overexpression
apoptosis modulation, MCF-7 cells, 1215

Cervical carcinoma
micronutrient plasma levels, 181
paclitaxel activity, 1285
peripheral blood lymphocyte CD3 γ expression, 1825
telomerase activity, 2023

Cervical intraepithelial neoplasia
micronutrient plasma levels, 181
CGP 41251
growth inhibition, glioblastoma, 1017, 1638

Chemosensitivity
apoptotic tumor cell death and, 623
-directed regional chemotherapy, prospective decision-aiding trial, 1469
enhancement by gene therapy, 1089

Chemosensitization
cyclosporine A, post-liver transplant patient plasma, 531

Chemosensitizers
P-glycoprotein inhibition, serum bioassay, 403

Chemotherapy: see also specific agents
bifunctional anthracene and nitrosourea, bladder cancer, 1315
combined with cyclosporine, intraocular retinoblastoma, 1499
differentiation-inducing telomerase inhibition, 799
high-dose
breast cancer treatment failure, Her2/ neu overexpression, 1509
-induced cell death modulation by growth factors, ovarian cancer, 1307
regional
chemosensitivity-directed, prospective decision-aiding trial, 1469
resistance
cytokeratin expression and, 97
standard-dose adjuvant
breast cancer treatment failure, Her2/ neu overexpression, 1509
ehB-IL2
effector cell activation, 1951

Children
acute lymphocytic leukemia
red blood cell methotrexate pharmacology, 331

Chloroacetamide
multidrug resistance protein modification, 1321

Choriocarcinoma
telomerase activity, 2023

Chromosome 3p
loss of heterozygosity, non-small cell lung cancer, 1185

Chromosome 4
aneuploidy, breast carcinoma, 883

Chromosome 6
aneuploidy, breast carcinoma, 883
long arm
loss of heterozygosity, breast cancer, 1601
short arm
rearrangement, melanoma, 641

Chromosome 7
aneuploidy, breast carcinoma, 883

Chromosome 8
aneusomy
breast carcinoma, 883
prostate carcinoma, 137
Chromosomes 9-12
aneusomy, breast carcinoma, 883
Chromosome 11p
microsatellite alterations, head and neck squamous carcinoma, 903
Chromosome 13q14
defeptions, B-cell chronic lymphocytic leukemia, 1673
Chromosome 17
aneusomy, breast carcinoma, 883
Chromosome 17p
loss of heterozygosity, medulloblastoma, 1559
Chromosome 18
aneusomy, breast carcinoma, 883
Chromosomes
-specific aneusomy
breast carcinoma, 883
prostate carcinoma, 137
Chromosome X
aneusomy, breast carcinoma, 883
Chromosome Y
aneusomies, prostate carcinoma, 137
Chronic obstructive pulmonary disease
serum anti-p53 antibodies, predating cancer, 1767
Cisplatin
accumulation and passive permeability, modulation by genistein, 991
cell death
modulation by growth factors, ovarian cancer, 1307
combined with ALR1057
antitumor effects, human oral squamous carcinoma xenografts, 511
cytotoxicity
9-aminocamptothecin poteniation, 687
UCN-01 enhancement, 791
gemcitabine interactions, 521
platinum-DNA adducts, ICP-MS quantitation, 1829
resistance
thioredoxin, 427
Clonality
bilateral breast cancer, 743
and transitional cell carcinoma
recurrence detection, 1795
c-myc
overexpression
colorectal carcinoma, 1049
thyroid carcinogenesis, 119
c-neu
overexpression
apoptosis modulation, MCF-7 cells, 1215
Colon
malignant
alkyltransferase, quantitative immunohistochemistry, 577
Colon adenocarcinoma
irinotecan combined with 5-fluorouracil or etoposide, xenograft models, 107
Colon carcinoma
adjuvant therapy
sulindac plus 5-FU and levamisole, 37
5'-AdTdh modulation of IdUrmd metabolism, xenografts, 981
cisplatin resistance
thioredoxin, 427
fluoropyrimidine efficacy and thymidylate synthase inhibition, murine 26-B tumors, 1327
growth inhibition by anti-EGF-related growth factor antisense oligonucleotides, 601
therapy
cytotoxicity, potentiation by wild-type p53, 1649
wild-type p53 dominance, 1639
Colon rhabdomyosarcoma
irinotecan combined with 5-fluorouracil or etoposide, xenograft models, 107
Colon tumors
fluoropyrimidine efficacy and thymidylate synthase inhibition, murine 26-B tumors, 1327
Colorectal carcinoma
c-myc overexpression, 1049
Glut1 overexpression, 1151
immunotherapy
active specific, Newcastle disease virus-infected autologous tumor cell vaccine, 21
metastases
dual antibody therapy with interferon, 1811
liver, c-src and c-yes activation, 1397
p53 point mutations, 1049
radiosensitization by adenosine wild-type p53, 1665
radiosensitization by 5-fluorocytosine, 53
Colorectal tumors
apoptosis, 1999
Complementary DNA
alkyltransferase
retroviral transfer, human hematopoietic progenitors, 1353
Costimulatory molecules
expression, lymphoma liver metastasis, 811
CPT-11: see Irinotecan
c-src activation, colorectal carcinoma liver metastases, 1397
CTL: see Cytotoxic T lymphocytes
Cyanine
tellurium-containing anticancer activity, mitochondria, 1335
Cyclic adenosine 3',5'-monophosphate-binding proteins
ovarian cancer, 201
Cyclin A
overexpression, esophageal squamous cell carcinoma, 1781
Cyclin D1
gene amplification
laryngeal squamous cell carcinoma, 175
prognostic significance, breast cancer, 1177
TNM-Gene, squamous cell carcinoma of esophagus, 1155
mRNA levels, breast cancer, 923
Cyclophosphamide
high-dose
cyclophosphamide and 4-hydroxycyclophosphamide kinetics, 1481
kinetics, high-dose cyclophosphamide chemotherapy, 1481
Cyclosporin
combined with chemotherapy, intraocular retinoblastoma, 1499
Cyclosporin A
chemosensitization, post-liver transplant patient plasma, 531
combined with carboplatin
refractory gynecologic cancer, phase 1 trial, 1699
refractory ovarian and fallopian tube cancer, phase II trial, 1693
prevention of MDR1 upregulation, 713
c-yes activation, colorectal carcinoma liver metastases, 1397
Cytarabine
combined with methotrexate
red blood cell pharmacology, acute lymphocytic leukemia in children, 311
continuous infusion
fludarabine interactions, 653
Cytokeratin
expression
and drug resistance, 97
Cytokines
serum levels, lung cancer, 553
Cytolysis
tumor cell, T-cell-mediated, 1001
Cytosine arabinoside
combined with B43-PAP, B-cell precursor leukemia, 1533
Cytosine deaminase
gene
5-fluorocytosine radiosensitization and, colorectal carcinoma, 53
Cytotoxicity
cisplatin
9-aminocamptothecin poteniation, 687
UCN-01 enhancement, 791
cisplatin combined with ALR1057, human oral squamous carcinoma xenografts, 511
potentiation by wild-type p53, colon cancer, 1649
TNF-B1(Fv) fusion protein activity, LeV antigen-expressing cells, 1523
Cytotoxic therapy
tumor cell proliferation, head and neck tumors, 1453
Cytotoxic T lymphocytes
mutant p53-specific, lung cancer cells, 877

D
Dacarbazine
DNA damage
peripheral white blood cells, malignant melanoma, 303
DCC
loss of expression, disseminated neuroblastoma, 1097
DDATHF: see Lometrexol
cis-Diaminedichloroplatinum(II): see Cisplatin
5,10-Dideazatetrahydrofolic acid: see Lomtrexol
Dietary folate
and folate receptor expression, neoplastic murine tissue, 1135
Dihydrofolate reductase
inhibitors
MDAM, antitumor effects, 707
Dihydroprymidine dehydrogenase
deficiency
5-fluorouracil neurotoxicity, 477
peripheral blood mononuclear cells and liver, 507
Dihydropyrimidinuria
asymptomatic adult, 1937
Dipyridamole
combined with PALA and flurouracil, advanced cancer, 1107
Dissemination
DCC loss of expression, neuroblastoma, 1097
Disulfide-stabilized Fv immunotoxins, 245
DNA
breast carcinoma content, flow cytometric analysis, 419
HSV-TK
combined with ganciclovir, melanoma, 47
DNA adducts
methyl
peripheral white blood cells, malignant melanoma treated with dacarbazine and hydroxyurea, 303
platinum
advanced germ cell cancer, 1063
ICP-MS quantitation, peripheral blood leukocytes, 1829
DNA damage
dacarbazine-induced
peripheral white blood cells, malignant melanoma, 303
p53 response
tamoxifen and, 1439
DNA repair
mismatch
genes, sporadic endometrial tumors, 1907
nucleotide excision
fluadrabine-mediated inhibition, and apoptosis, 1731
peripheral white blood cells, malignant melanoma treated with dacarbazine and hydroxyurea, 303
Docetaxel
refractory advanced ovarian carcinoma, phase II study, 837
Doxorubicin
MRP-mediated drug resistance
glutathione depletion and, 1961
pharmacodynamics, bladder tumors, 1275
resistance
cytokeratin expression and, 97
PAK-104P reversal, 369
Drug interactions
cisplatin and gemcitabine, 521
fluorouracil and continuous infusion cytarabine, 653
Drug resistance: see also Multidrug resistance; specific drugs
cytokeratin expression and, 97
Drugs: see also specific drugs
drug-induced apoptosis
modulation by PKC signal transduction pathway, 1915
exposure after intraperitoneal administration
vasopressin and, 311
intraperitoneal
pharmacokinetics, vasopressin and, 311
Dysplasia: see also Myelodysplastic syndrome
cervical
micronutrient plasma levels, 181
Eastern Cooperative Group Trial
IFN-γ, metastatic melanoma, 29
Edatrexate
high-dose
combined with oral leucovorin, phase I trial, 1819
Effector cells
activation by anti-GD2-IL2 fusion protein, 1951
e23(Fv)PE38KDEL
lung cancer activity, 75
orthotopic human lung cancer, 1851
EGF: see Epidermal growth factor
Endometrial carcinoma
abnormal glycolipid expression,
quantitative assay, 749
and tamoxifen, 223
telomerase activity, 2023
malignant tumor blood vessel markers
espinophil peroxidase, 1867
Endometrial tumors
sporadic
DNA mismatch repair genes, 1907
Endometrium
MDR1 expression, 1981
Endothelial growth factor
vascular
intestinal-type gastric cancer, 1679
mRNA expression, lung cancer, 1411
serum levels, 821
Enzyme-linked immunosorbent assay
p53 protein
prognostic significance, non-small cell lung cancer, 155
Eosinophil peroxidase
tumor blood vessels, ovarian and endometrial cancers, 1867
Epidermal growth factor
anti-EGF-related growth factor antisense oligonucleotides
growth inhibition, colon carcinoma, 601
131I-labeled
squamous lung carcinoma
radioisotonic localization, 13
receptor
expression, metaplastic bronchial epithelium, 1787
gene amplification, esophageal squamous cell carcinoma, 909
Epithelial cells
mammary
lymphokine-activated killing sensitivity, 207
ovarian
malignant, p21 expression and p53 mutation, 1571
Epithelial ovarian carcinoma
refractory to platinum
docetaxel, phase II study, 837
Epithelium
androgen and glucocorticoid receptors,
prostatic hyperplasia and carcinoma, 889
metaplastic bronchial
EGF expression, 1877
Epitopes
T-cell
melanoma, detection, 87
erbB-2
anti-erbB-2 oncotxin
lung cancer, 75
orthotopic human lung cancer, 1851
erbB-3
receptors
tumor cells expressing, T cell-mediated cytolysis, 1001
erbB-4
receptors
tumor cells expressing, T cell-mediated cytolysis, 1001
Erythrocytes
glucose transporter
overexpression, colorectal carcinogenesis, 1151
methotrexate pharmacology, acute lymphocytic leukemia in children, 331
Erythropoiesis
stimulation by stem cell factor,
myelodysplastic syndrome, 1031
Esophageal squamous cell carcinoma
cyclin A overexpression, 1781
cyclin D1 gene amplification, TNM-Gene, 1155
EGFR gene amplification, 909
Estrogen
plasma
suppression by megestrol acetate, postponopausal breast cancer, 1515
receptors
FES-PET and, breast cancer, 933
gene methylation, breast tumors, 805
mRNA levels, breast cancer, 923
status, angiogenesis determination and, 1191
variant and wild-type, ovarian carcinoma, 2029
3-Ethyl-3'-methyl-thiatelluracarbocyanine iodide
anticarcinoma activity, mitochondria, 1335
7-Ethyl-10-[4-[(1-piperidino)1-piperidino]carboxyloxy-campothecin: see Irinotecan
Etosopide
combined with irinotecan, colon adenocarcinoma or rhabdomyosarcoma xenograft models, 107
Fallopian tube cancer
refractory
carboplatin combined with
cytoxan, A, phase II trial, 1693

Fatty acids
aromatic
multidrug resistance vulnerability, 865
omega-3
suppressive effects, breast cancer, 1751

Fc
recombinant human TNF receptor
chimaera
combined with IL-2, phase I trial, 1341

FDG: see 2-[18F]fluoro-2-deoxy-d-glucose

FES: see 16α-[18F]fluoro-17β-estradiol

Fibronectin
serum levels, immunotoxin therapy, 1705

Flavonoids
quercetin, phase I clinical trial, 659

Flow cytometry
DNA/RNA content, breast carcinoma, 419
GGG918 inhibition by Pgp, 7

Flow resistance
gemcitabine, small cell lung cancer, 359

Fludarabine
cytarabine interactions, 653
nucleotide excision repair inhibition
and apoptosis, quiescent lymphocytes, 1731

Fluorescence in situ hybridization
chromosomal aneuploidies, prostate
prostate carcinoma, 137
chromosome 13q14 deletions, B-cell
chronic lymphocytic leukemia, 1673
dual-color
trisomy 7, prostate cancer, 1553

5-Fluorouracil
radioisotopization, colorectal carcinoma, 53

2-[18F]fluoro-2-deoxy-d-glucose
posterior emission tomography, breast
cancer, 933

16α-[18F]fluoro-17β-estradiol
posterior emission tomography, breast
cancer, 933

Fluoropyrimidine
therapeutic efficacy
and thymidylate synthase inhibition,
colon 26-B tumors, 1327

Fluorouracil
combined with iodosoxyuridine and
leucovorin, phase I trial, 1475
combined with PALA and dipyridamole,
advanced cancer, 1107

5-Fluorouracil
catabolism
hepatic, 19F MRS quantitation, 339
combined with irinotecan, colon
denocarcinoma or
rhabdomyosarcoma xenograft models, 107
combined with levamisole and sulindac,
colon carcinoma, 37
cytotoxicity
potentiation by wild-type p53, colon
cancer, 1649
neurotoxicity, dihydropyrimidine
dehydroygenase deficiency, 477
prodrug tagetar
combined with uracil, phase I and
pharmacokinetic study, 1461

Folate
analogue thymidylate synthase
inhibitors, 227
dietary
and folate receptor expression,
neoplastic murine tissue, 1135
receptors
dietary folate and, neoplastic murine
tissue, 1135

Folate hydrolase
prostate-specific membrane antigen,
prostatic carcinoma cells, 1445

Folnic acid rescue
combined with lometrexol, phase I
study, 1123

5-FU: see 5-Fluorouracil

Fusion protein
anti-GD2-IL-2
effector cell activation, 1951
GM-CSF/IL-3
effects on human tumor colony-
forming units, 1713

TNF-B1(Fv), 1523

Fv immunotoxins
disulfide-stabilized, 245
e23Fv-PE38KDEL
l lung cancer activity, 75
orthotopic human lung cancer, 1851
recombinant
antibody engineering, 245

TFN-B1(Fv)
cytotoxic antitumor activity, Le
antigen-expressing cells, 1523

G

GAGE
expression, gastric carcinoma, 1619

Gallium nitrate
resistance
transferrin and Ga-PIH and, lymphoid
leukemic cells, 1009

Gallium-pyridoxal isonicotinoyl
hydrazine
and resistance to gallium nitrate,
lymphoid leukemic cells, 1009

Ganciclovir
combined with HSV-TK gene transfer,
melanoma, 47

Ganglioside
GD2
anti-GD2-IL-2 fusion protein, effector
cell activation, 1951

GD3
BEC2 anti-idiotypic antibody mimic,
melanoma, 679

Galectin-1
expression, 1619

cisplatin resistance
thioredoxin, 427

intestinal-type
angiogenesis, 1679

K-sam protein, immunohistochemical
detection, 1373

Gemcitabine
infusion pharmacokinetics and
metabolism, small cell lung cancer, 359
interactions with cisplatin, 521

Genes: see also Oncogenes; Proto-
oncogenes
androgen receptor (AR)
mutations, prostate cancer, 277

BAGE
expression, gastric carcinoma, 1619
cyclin D1 (CCND1)
amplification, breast cancer, 1177
amplification, laryngeal squamous cell
carcinoma, 175
amplification, TNM-Gene, 1155
expression, breast cancer, 293
cytosine deaminase
5-fluorouracil radiosensitization
and, colorectal carcinoma, 53

DCC
loss of expression, disseminated
neuroblastoma, 1097
DNA mismatch repair, sporadic
endometrial tumors, 1907
epidermal growth factor receptor
(EGFR)
amplification, esophageal squamous
carcinoma, 909

estrogen receptor (ER)
expression, breast cancer, 923
methylated, breast tumors, 805

GAGE
expression, gastric carcinoma, 1619

K-ras
mutations, lung carcinoma, 411
mutations, non-small cell lung
carcinoma, 1083

MAGE
expression, gastric carcinoma, 1619

MDR
transfer into peripheral blood
progenitor cells, 873

MDR1
bisanthrene resistance, 973
expression, breast carcinoma, 1231
expression, endometrium, 1981
upregulation prevention by
cyclosporin A and PSC 833, 713

MRP
expression, breast carcinoma, 1231

p16
expression, breast cancer, 1993

p19
expression, breast cancer, 1993

p53
endogenous mutant CTLA target, lung

carcinoma cells, 877
human papilloma virus and, head and
neck cancer, 755
mutations, bladder cancer, 1055
mutations, p21 expression and, 1571
mutations, recurring head and neck
cancer, 1577

point mutations, colorectal carcinoma, 1049

pI07
expression, lung cancer, 1239

polyADP-ribose polymerase (PARP)
expression and genomic instability, breast cancer, 1163
pRb/p105 expression, lung cancer, 1239
pRb/p130 expression, lung cancer, 1239
progestosterone receptor (PR) methylation, breast tumors, 805
retinoblastoma family expression, lung cancer, 1239
retinoblastoma (RB) expression, lung cancer, 1239
somatostatin receptor type 2 expression, neuroblastoma, 1757
TAP
MHC class I and, renal cell carcinoma, 1427
TNR1
expression and adverse prognosis, non-small cell lung cancer, 1369
TNM-Gene cyclin D1 gene amplification, squamous cell carcinoma of esophagus, 1155
tumor antigen expression, gastric carcinoma, 1619
wild-type p53 adenovirus, radiation sensitization, 1665
Gene therapy chemosensitivity enhancement, 1089
topical head and neck squamous cell carcinoma, organotypic model, 1659
Gene transfer liposome-mediated active immunotherapy, breast and ovarian cancer, 59
retroviral MDR1 bisanthrene resistance, 973
retroviral MDR, peripheral blood progenitor cells, 873
retroviral MGMT, human hematopoietic progenitors, 1353
virus-free HSV-TK combined with ganciclovir, melanoma, 47
Genistein modulation of cisplatin accumulation and passive permeability, 991
Genomic instability leukemia, 1583
PARP expression and, breast cancer, 1163
Germ cell cancer advanced platinum-DNA adducts, 1063
Germ cell tumors metastatic nonseminomatous serum tumor marker half-life, 1565
GG918 Pgp inhibition, flow cytometric assay, 7
Glioblastoma growth inhibition by CGP 41251, 1017, 1638
Glioblastoma multiforme recurrence low-grade, biological and molecular analysis, 187
Glioma malignant hypericin-enhanced radiosensitivity, 843
recurrent, high-dose 13-cis-retinoic acid treatment, 1931
recurrent, high-dose tamoxifen treatment, 619
Glucocorticoid receptors prostatic hyperplasia and carcinoma, 889
Glucose erythrocyte transporter overexpression, colorectal carcinogenesis, 1151
Glutathione depletion and multidrug resistance protein function, 1961
Glutathione S-transferase immunohistochemical staining, head and neck cancer, 1859
Glut1 protein overexpression, colorectal carcinogenesis, 1151
Glycophorin abnormal endometrial expression, quantitative assay, 749
Glycoprotein 75 cell surface target, melanoma, 1837
GM-CSF: see Granulocyte-macrophage colony-stimulating factor
Granulocyte colony-stimulating factor combined with topotecan, phase I trials, 1489
serum levels, lung cancer, 553
Granulocyte-macrophage colony-stimulating factor CD8 T-cell release melanoma T-cell epitope detection and, 87
combined with IL-2, phase II study, 319
GM-CSF/IL-3 fusion protein effects on human tumor colony-forming units, 1713
serum levels, lung cancer, 553
Growth factor EGF-related anti-EGF-related growth factor antisense oligonucleotides, colon carcinoma, 601
epidermal 1251I-labeled, squamous lung carcinoma radiolocalization, 13 receptor expression, metaplastic bronchial epithelium, 1787
receptor gene amplification, esophageal squamous cell carcinoma, 909
insulin-like, 1 regulation by ICI 182780, 2037
lipid cisplatin-induced cell death modulation, ovarian cancer, 1307
modulation gene therapy strategy and chemosensitivity enhancement, 1089
paracrine interleukin 6, breast carcinoma, 215 peptide
cisplatin-induced cell death modulation, ovarian cancer, 1307 platelet-derived β receptors, breast carcinoma, 773
transforming, β2 stimulation by TNF-α. MCF-7 cells, 827
vascular endothelial intestinal-type gastric cancer, 1679 mRNA expression, lung cancer, 1411
serum levels, 821
Gynecologic cancer refractory intravenous carboplatin and cyclosporin A, phase I trial, 1699
telomerase activity, 2023
Head and neck cancer glutathione S-transferase staining, 1859
Head and neck squamous cell carcinoma antitumor effects of cisplatin combined with ALR1T1057, human xenografts, 511
apoptosis by ATRA and 4HP, 855
cytotoxic therapy tumor cell proliferation, 1453
early stage radiotherapy, bcl-2 protein and prognostic significance after, 261
growth stimulation by interleukin 4, 127
diabetes mellitus and virus p53, 755
microsatellite alterations at lpl loci, 903
recurrence p53 mutations, 1577
topical gene therapy, organotypic model, 1659
Head and neck tumors cytotoxic therapy tumor cell proliferation, 1453
Heat shock protein 27 prognostic significance, node-negative breast cancer, 1199
Hematological neoplasia replication errors, 1583
Hematopoietic progenitor cells autologous breast cancer treatment failure, Her2/ neu overexpression, 1509
human retroviral MGMT gene transfer, 1353
Hematotoxicity bisanthrene-specific resistance, retroviral MDR1 gene transfer, 973
Hepatocellular carcinoma chemosensitization cyclosporin A, post-liver transplant patient plasma, 531
multidrug resistance, murine model, 695
Hepatoma multidrug resistance, murine model, 695
HER2 overexpression apoptosis modulation, MCF-7 cells, 1215
HER2/neu oncotoxin, orthotopic human lung cancer, 1851
Hypoxanthine-guanine
N-(4-Hydroxyphenyl)retinamide
Hyperplasia
Hypericin
Hydroxyurea
Hybrid
Hyaluronan
Human
HT-29
HSV: HSP:
Hormones
HLA:
Herpes
IGF-IR
prostatic
cisplatin-induced
apoptosis
and
directed regional chemotherapy,
prospective decision-aiding trial, 1469
Hyaluronic
receptor expression, pancreatic cancer
cells, 1607
Hybrid protein
pml/RAR-α
immune recognition, acute
promyelocytic leukemia, 593
4-Hydroxyxystaurosporine
cisplatin-induced cytotoxicity and, 791
Hydroxyurea
combined with dacarbazine
DNA damage, malignant melanoma, 303
Hypertetin
enhanced radiosensitivity, malignant
glioma cells, 843
Hyperplasia
prostatic
androgen and glucocorticoid receptors, 889
Hypoxanthine-guanine phosphoribosyltransferase
mutations
peripheral white blood cells,
malignant melanoma, 303

ICP-MS: see Inductively coupled plasma mass spectroscopy
IdUr: see Iododeoxyuridine
IFN: see Interferon
IGF: see Insulin-like growth factor
IL: see Interleukin
Immune recognition
pml/RAR-α. acute promyelocytic leukemia, 593
tumor escape, melanoma, 641
Immunity
cell-mediated, lymphocytes, 785
Immunization
BEC2 anti-idiotypic vaccine, melanoma, 679
Immunodeficiency
severe combined
B-cell precursor leukemia, B43-PAP
plus cytokine arabinoside treatment, 1533
multidrug resistance, murine hepatoma model, 695
Immunoglobulin G
recombinant human TNF receptor chimera
combined with IL-2, phase I trial, 1341
Immunohistochemistry
glutathione S-transferase staining, head and neck cancer, 1859
K-sam protein detection, stomach cancer, 1373
MDR1 expression, endometrium, 1981
M, 67,000 expression, thyroid cancer, 1777
p21 and p53 expression, breast carcinoma, 1591
predictors of occult neck metastases, laryngeal carcinoma, 1801
quantitative
alkyltransferase, malignant colon, 577
steroid receptors, prostatic hyperplasia and carcinoma, 889
TGFβ-II levels, prostate cancer, 635
Immunomagnetic purging
peripheral blood progenitor cells, breast cancer, 81
Immunoreactivity
Mel-CAM, mesenchymal neoplasms, 569
Immunostaining
clustered p53, prostate carcinoma, 399
Immunotherapy
active
gene modification of tumor cells,
breast and ovarian cancer, 50
active specific
Newcastle disease virus-infected autologous tumor cell vaccine, colorectal carcinoma, 21
melanoma
TCR-Vβ repertoire after, 767
metastatic melanoma
signaling activity in T cells before and after, 1263
serum fibronectin levels, 1705
Immunotoxins
e23(Fv)PE38KDEL
lung cancer activity, 75
orthotopic human lung cancer, 1851
Fv
disulfide-stabilized, 245
recombinant, antibody engineering, 245
ricin A chain-containing
treatment, serum fibronectin levels, 1705
TNF-B1(Fv)
cytotoxic antitumor activity, LeY
antigen-expressing cells, 1523
Inductively coupled plasma mass spectroscopy
quantitation of platinum-DNA adducts, peripheral blood leukocytes, 1829
Insulin-like growth factor 1
receptor regulation by ICI 182780, 2037
Interferon
dual antibody therapy with, metastatic colorectal cancer, 1811
Interferon γ
metastatic melanoma trial, 29
Interleukin 1
receptor antagonist induction after IL-1 therapy, 501
Interleukin 2
anti-GD2-IL2 fusion protein
effector cell activation, 1951
combined with GM-CSF, phase IB study, 319
combined with rhuTNF-Fc, phase I trial, 1341
immunotherapy
combined with local radiation, murine renal carcinoma, 1543
T-cell signaling activity, metastatic melanoma, 1263
TCR-Vβ repertoire after, melanoma, 767
inhaled natural, pulmonary malignancy, 1115
liposomes
aerosol delivery, canine studies, 721
low-dose daily subcutaneous injections, toxicity and immunological effects, 669
and natural killer cells, metastatic cancer, 493
non-MHC-restricted lymphokine-activated killing sensitivity, MCF-10A cells, 207
Interleukin 3
GM-CSF/IL-3 fusion protein
effects on human tumor colony-forming units, 1713
subcutaneous recombinant human refractory malignancy, phase I trial, 347
Interleukin 4
growth stimulation, head and neck squamous cell carcinoma, 127
Interleukin 6
anti-IL-6 receptor antibodies
combined with retinoids, myeloma and, 253
growth-stimulatory factor, melanoma, 1417
levels, lung cancer, 553
levels, metastatic malignant melanoma, 1405
paracrine growth factor, breast carcinoma, 215
Interleukin 10
TIMP1 expression and adverse prognosis, 1369
prognostic markers
K-ras mutations, 411
thrombomodulin, 763
retinoblastoma gene family expression, 1239
second, genetic analysis, 1103
serum cytokine levels, 553
small cell
gemcitabine pharmacokinetics and metabolism, 359
squamous 131I-labeled EGF radiolocalization, 13
vascular endothelial growth factor mRNA expression, 1411
Lung tumors
cathepsins, 561
inhaled nIL-2, phase I trial, 1115
polyamine analogue-induced cell death, 441
Lycopene
plasma levels, cervical intraepithelial neoplasia and cancer, 181
Lymphatic drug exposure
after intraperitoneal administration vasopressin and, 311

Lymph nodes
metastases
Glut1 overexpression and, colorectal carcinogenesis, 1151
T, breast cancer, 1887
node-negative breast cancer hsp27, 1199
Ki-67 vs S-phase fraction, 585
p53 expression, prognostic value, 2007
node-positive breast cancer adjuvant tamoxifen, predictors of outcome, 1191
treatment failure, Her2Neu overexpression, 1509
Lymphocytes: see also B cells; T cells
activation by anti-GD2-IL2 fusion protein, 1951
peripheral blood CD3/ξ expression, cervical cancer, 1825
pml/RARα immune recognition, acute promyelocytic leukemia, 593
quiescent apoptosis, fludarabine and, 1731
tumor-associated signal transduction defects, ovarian carcinoma, 161
tumor cell killing, 785
Lymphoid leukemia
gallium nitrate resistance, transferrin and Ga-PIH and, 1009
Lymphokine-activated killing sensitivity moduation by oncogenes and protein kinase A subunits, MCF-10A cells, 207
Lymphoma
liver metastasis adhesion and costimulatory molecule expression, 811
Lymphoma, B-cell recurrent 99mTc-labeled anti-CD20 mAb therapy, 457

M
Macrophage colony-stimulating factor recombinant continuous-infusion, metastatic melanoma, 295
serum levels, lung cancer, 553
MAGE expression, gastric carcinoma, 1619
Magnetic resonance spectroscopy three-dimensional localized 19F hepatic 5-fluorouracil catabolism quantitation, 339
Major histocompatibility complex class I and LMP and TAP genes, renal cell carcinoma, 1427
Malignancy
colon
alkyltransferase, quantitative immunohistochemistry, 577
glioma
hypercin-enhanced radiosensitivity, 843
recurrent, high-dose 13-cis-retinoic acid treatment, 1931
recurrent, high-dose tamoxifen treatment, 619
lung tissue
cathepsins, 561
melanoma
CD44 variant isoforms, 447
dacarbazine-induced DNA damage, peripheral white blood cells, 303
metastatic continuous-infusion recombinant M-CSF, phase I study, 295
IFN-γ trial, 29
signaling deficiency, T cells, 1263
metastatic malignant IL-6 levels, 1405
refractory carmustine and streptozocin, 1129
T-cell epitopes, detection, 87
treatment HSVG-T DNA and ganciclovir, 47
melanosomal protein cell surface target, 1837
Melanosomal protein
cell surface target, 1837
Mel-CAM
immunoreactivity, mesenchymal neoplasms, 569
Melphalan
high-dose, multiple myeloma, 947
resistance
cytokeratin expression and, 97
Mesenchymal neoplasms
Mel-CAM immunoreactivity, 569
Messenger RNA
CD44 isoforms, thyroid and breast carcinoma, 1251
cyclin D1 and estrogen receptor levels, breast cancer, 923
MDR1 expression, endometrium, 1981
vascular endothelial growth factor expression, lung cancer, 1411
Metabolism
gemcitabine, small cell lung cancer, 359
irinotecan, 1943
Metaplasia
bronchial epithelium
EGFr expression, 1787
Metastasis
breast cancer

M-CSF: see Macrophage colony-stimulating factor
MDAM: see γ-Methylene-10-deazaaminopterin
MDA-MG-468 cells
paclitaxel-induced death, 847
MDR: see Multidrug resistance
Medulloblastoma
chromosome 17p loss of heterozygosity, 1559
Megestrol acetate
plasma estrogen suppression, postmenopausal breast cancer, 1515
Melanoma
advanced-stage IL-6 growth-stimulatory factor, 1417
chromosome 6 rearrangement, 641
HLA-A2 loss, 641
immunization BEC2 anti-idiotypic vaccine, 679
immunotherapy
TCR-Vβ repertoire after, 767
interleukin 10 antiangiogenic effects, 1969
interleukin 10 production, 1383
malignant CD44 variant isoforms, 447
dacarbazine-induced DNA damage, peripheral white blood cells, 303
metastatic continuous-infusion recombinant M-CSF, phase I study, 295
IFN-γ trial, 29
signaling deficiency, T cells, 1263
metastatic malignant IL-6 levels, 1405
refractory carmustine and streptozocin, 1129
T-cell epitopes, detection, 87
treatment HSVG-T DNA and ganciclovir, 47
melanosomal protein cell surface target, 1837

Clinical Cancer Research 2065
omega-3 fatty acid suppressive effects, 1751
colorectal cancer
dual antibody therapy with interferon, 1811
interleukin 2 effects on natural killer cells, 493
liver
src and yes, colorectal carcinoma, 1357
lymph node
Glu1 overexpression and, colorectal carcinogenesis, 1151
T, breast cancer, 1887
lymphoma
adhesion and costimulatory molecule expression, liver, 811
malignant melanoma
IL-6 levels, 1405
melanoma
continuous-infusion recombinant M-CSF, phase I study, 295
IFN-γ trial, 29
signaling deficiency, T cells, 1263
suppression by IL-10, 1969
neck
occult, laryngeal carcinoma, 1801
nonseminomatous germ cell tumors
serum tumor marker half-life, 1565
occult neck
laryngeal carcinoma, 1801
prostatic carcinoma
variants, orthotopic implantation in nude mice, 1627
pulmonary
local tumor irradiation combined with IL-2 therapy and, murine renal carcinoma, 1543
Methotrexate
pharmacology
red blood cell, acute lymphocytic leukemia in children, 331
Methylation
ER and PR genes, breast tumors, 805
Methylinators
resistance
MGMT and, brain tumor cell lines, 735
Methyl DNA adducts
peripheral white blood cells, malignant melanoma treated with dacarbazine and hydroxyurea, 303
γ-Methylenedinitro-1-deazaaminopterin
antitumor effects, preclinical evaluation, 707
O⁶-Methylguanine-DNA methyltransferase
and brain tumor cell line methylator resistance, 735
retroviral gene transfer, human hematopoietic progenitors, 1353
Mevalonate
inhibitor lovastatin, phase I study, 483
MGMT: see O⁶-Methylguanine-DNA methyltransferase
MIB-1
and occult neck metastases, laryngeal carcinoma, 1801
tumor cell proliferation rate, breast carcinoma, 147
Micronutrients
plasma levels, cervical intraepithelial neoplasia and cancer, 181
Microsphere alterations
leukemia and myelodysplastic syndrome, 1583
lp loci, head and neck squamous carcinoma, 903
Microsphere instability
sporadic endometrial tumors
DNA mismatch repair genes, 1907
Microvessel count
prognostic model, non-small cell lung carcinoma, 1067
Mitochondria
Te anticarcinoma activity, 1335
Mitomycin C
resistance
cytokeratin expression and, 97
Mitoxantrone
resistance
cytokeratin expression and, 97
Molecular screening
p53 mutations, multifocal transitional cell carcinoma of bladder, 1795
Monoclonal antibody
anti-CD20
γ-Galactosylated, recurrent B-cell lymphoma therapy, 457
antitumor 81C6 intrathelial lymphoma, phase II trial therapy, 963
M1
TNF-B1(Fv) fusion protein, cytotoxic antitumor activity, 1523
BEC2 anti-idiotypic immunization, melanoma, 679
5C3
TrkA protein detection, neuroblastoma, 1361
MIB-1
and occult neck metastases, laryngeal carcinoma, 1801
tumor cell proliferation rate, breast carcinoma, 147
γ-γ-CYT-356
hormone-refractory prostate cancer treatment, 1289
Mononuclear cells
peripheral blood
dihydropyrimidine dehydrogenase activity, 507
N²-[4-(Morpholinosulfonyl)benzyl]-N⁶-methyl-2,6-diaminobenzo-[c,d]-indole glutarate: see AG331
M, 67,000
expression, thyroid cancer, 1777
mRNA: see Messenger RNA
MRP: see Multidrug resistance protein
MRS: see Magnetic resonance spectroscopy
MUC18: see Mel-CAM
Multidrug resistance
inhibitor GC918
Pgp inhibition, flow cytometric assay, 7
MDR gene
transfer into peripheral blood progenitor cells, 873
MDR1 gene
expression, breast carcinoma, 1231
expression, endometrium, 1981
retroviral transfer, bisantrene resistance, 973
upregulation prevention by cyclosporin A and PSC 833, 713
MRP-mediated
modulation by acrolein and chloroacetaldehyde, 1321
PAK-104P reversal, 369
murine hepatoma model, 695
multidrug resistance
vulnerability to aromatic fatty acids, 865
Multidrug resistance protein
gene expression, breast carcinoma, 1231
glutathione depletion and, 1961
Multidrug resistance modulation by acrolein and chloroacetaldehyde, 1321
PAK-104P reversal, 369
Multiforme, glioblastoma
reoccurrence
low-grade, biological and molecular analysis, 187
Multiple myeloma
high-dose melphalan, 947
Mutations
AR, prostate cancer, 277
dNA mismatch repair gene, sporadic endometrial tumors, 1907
hypoxanthine-guanine phosphoribosyl transferase
peripheral white blood cells, malignant melanoma treated with dacarbazine and hydroxyurea, 303
K-ras
lung carcinoma, 411
non-small cell lung carcinoma, 1083
p53
bladder cancer, 1055
dendogenous, CTL target, 877
expression, soft tissue sarcoma, 1391
molecular screening, multifocal transitional cell carcinoma of bladder, 1795
p21 expression and, malignant ovarian epithelial cells, 1571
recurring head and neck cancer, 1577
point
p53, colorectal carcinoma, 1049
Myelodysplastic syndrome
crythromelobiosis stimulation by stem cell factor, 1031
microsphere alterations, 1583
Myeloma
all-trans retinoic acid and antireceptor antibodies and, 253
Myeloma, multiple
high-dose melphalan, 947

N

Natural killer cells
CD3 ξ expression, cervical cancer, 1825
expansion by daily subcutaneous low-dose IL-2, 609
interleukin 2 effects, metastatic cancer, 493
tumor-associated
signal transduction defects, ovarian carcinoma, 161
Neck
metastases occult, laryngeal carcinoma, 1801
Neoplasia, cervical intraepithelial
micronutrient plasma levels, 181
Neuroblastoma: see Tumors
Neu/erbB-2 receptors
tumor cells expressing, T cell-mediated cytolyis, 1001
Neuroblastoma dissemination
DCC loss of expression, 1097
somatostatin receptor type 2 expression, 1757
TrkA protein detection by mAb 5C3, 1361
Neurotoxicity 5-fluouracil, dihydroprymidine dehydrogenase deficiency, 477
Newcastle disease virus infected autologous tumor cell vaccine active specific immunotherapy, colorectal carcinoma, 21
Nitrosourea bifunctional chemotherapy with anthracycline, bladder cancer, 1315 resistance retroviral MGMT gene transfer, human hematopoietic progenitors, 1353
Non-small cell lung carcinoma advanced paclitaxel, phase II study, 941 anti-erbB-2 effects, orthotopic human, 1851 bcl-2 protein expression, 915 chromosome 3p loss of heterozygosity, 1185 K-ras mutations, 1083 p53 protein expression prognostic significance, 155 retinoblastoma and, 1169 and survival time, 915 prognosis biological parameters, model, 1067 retinoblastoma protein expression, 1169 TIMP1 expression and adverse prognosis, 1369 NSC 615291: see Bizelesin
Nuclear antigen proliferating cell and occult neck metastases, laryngeal carcinoma, 1801 truncated p21 adenovirus, growth suppression, 1221
Nucleotide excision repair fludarabine-mediated inhibition and apoptosis, quiescent lymphocytes, 1731 suppressive effects, breast cancer, 1751 Oncogenes: see also Genes; Proto-

\[ P \]

\[ p^{\text{EGR1}} \]
expression, breast cancer, 1993
\[ p^{\text{BRCA1}} \]
expression, breast cancer, 1993
Phenylacetate
multidrug resistance vulnerability, 865
Phenylbutyrate
apoptosis induction, prostate cancer, 379
multidrug resistance vulnerability, 865
Phorbol ester tumor promoter
growth inhibition, glioblastoma, 1017,
1638
N-Phosphonacetyl-L-aspartate
combined with fluorouracil and
dipyrimadole, advanced cancer, 1107
PIX321
effects on human tumor colony-forming
units, 1713
PKC: see Protein kinase C
Placental site trophoblastic tumor
molecular analysis and clinical
experience, 897
Plasma
cyclosporin A chemosensitization, post-
liver transplant, 531
drug exposure
intraperitoneal, vasopressin and, 311
estrogen
suppression by megesterol acetate,
postmenopausal breast cancer, 1515
micronutrient levels, cervical
intraepithelial neoplasia and cancer,
181
topotecan study, 1489
Platelet-derived growth factor
β receptors, breast carcinoma, 773
Platinum
combined with cyclosporin A, refractory
ovarian and fallopian tube cancer, 1693
DNA adducts
advanced germ cell cancer, 1063
ICP-MS quantitation, peripheral blood
leukocytes, 1829
head and neck cancer chemotherapy,
GST staining and, 1859
refractory advanced ovarian carcinoma
docetaxel, phase II study, 837
Poly(ADP-ribose) polymerase
gene expression
and genomic instability, breast cancer,
1163
Polyamine analogues
-induced cell death, lung tumor cells,
441
Polymerase chain reaction
reverse transcription-
MDR1 expression, endometrium, 1981
somatostatin receptor type 2
expression, neuroblastoma, 1757
Positron emission tomography
FGD and FES, breast cancer, 933
Progenitor cells
hematopoietic
breast cancer treatment failure, Her2/
new overexpression, 1509
retroviral MGMT gene transfer, 1353
peripheral blood
immunomagnetic purging, breast
cancer, 81
MDR transfer into, 873
Progestosterone receptors
gene methylation, breast tumors, 805
Proliferating cell nuclear antigen
and occult neck metastases, laryngeal
carcinoma, 1801
truncated p21 adenovirus
growth suppression, 1221
Proliferative breast disease
vasculature, 1873
Prostate-specific antigens
-producing prostatic carcinoma
xenograft LuCap 23, characterization,
1039
Prostate-specific membrane antigen
folate hydrolase, prostatic carcinoma
cells, 1445
Prostatic carcinoma
androgen and glucocorticoid receptors,
889
apoptosis
phenylbutyrate induction, 379
AR gene mutations, 277
bcl-2 protein expression, 389
chromosomal aneuploidy, prognostic
value, 137 clustered p53 immunostaining, 399
hormone-refractory
"o-Y-CYT-356 treatment, 1289
metastatic variants, orthotopic
implantation in nude mice, 1627
progression
trisomy 7 marker, 1553
prostate-specific membrane antigen
folate hydrolase, 1445
TGF-β1 receptor expression, 1255
TGFβR-II levels, 635
xenografts
LuCap 23, characterization, 1039
Prostatic hyperplasia
androgen and glucocorticoid receptors,
889
Proteases
prognostic markers, 613
Protein: see also Oncoprotein
anti-GD2-II-2
effector cell activation, 1951
bcl-Xt.
-induced apoptosis, MCF-7 cells,
1215
CD44
mRNA isoforms, thyroid and breast
carcinoma, 1251
cyclic AMP-binding, ovarian cancer,
201
Glut1
overexpression, colorectal
carcinogenesis, 1151
glycoprotein 75
cell surface target, melanoma, 1837
GM-CSF/IL-3
effects on human tumor colony-
forming units, 1713
keratin 18
expression, breast cancer, 1879
K-sam
immunohistochemical detection,
stomach cancer, 1373
low molecular weight
MHC class I and, renal cell
carcinoma, 1427
melanosomal
cell surface target, 1837
multidrug resistance

gene expression, breast carcinoma, 1231

glutathione depletion and, 1961
multidrug resistance, PAK-104P reversal, 369

P-glycoprotein
inhibition, serum bioassay, 403
inhibition by GG918, flow cytometric assay, 7

pm/RAR-α
immune recognition, acute promyelocytic leukemia, 593

retinoblastoma
alterations, non-small cell lung carcinoma, 1169
signal-transducing
defects, tumor-associated lymphocytes, ovarian carcinoma, 161
TNF-B1(Fv)
cytotoxic and antitumor activity, LeY antigen-expressing cells, 1523
TrkA
detection by mAb SC3, neuroblastoma, 1361

Protein kinase A
subunits
lymphokine-activated killing sensitivity and, MCF-10A cells, 207

Protein kinase C
inhibitor CGP 41251
growth inhibition, glioblastoma, 1017, 1638
signal transduction pathway
drug-induced apoptosis modulation, 1915

Protein tyrosine kinase
pp60-src
activation, colorectal carcinoma liver metastases, 1397
pp62-src
activation, colorectal carcinoma liver metastases, 1397

Proto-oncogenes
c-myc
overexpression, colorectal carcinoma, 1049

PSC 833
prevention of MDR1 upregulation, 713

Purging
immunomagnetic
peripheral blood progenitor cells, breast cancer, 81

Pyrimidine
urinary levels, 1937

Radiation
cytotoxicity
potentiation by wild-type p53, colon cancer, 1649

local
combined with IL-2, murine renal carcinoma, 1543
sensitization by adenovirus wild-type p53, colorectal cancer, 1665

Radiosensitivity
hypericin-enhanced, malignant glioma cells, 843

Radiosensitization
5-fluorocytosine, colorectal carcinoma, 53
5-iododeoxyuridine
leucovorin modulation, phase I study, 1299

Radiotherapy
eye stage head and neck cancer
bcl-2 protein, 261
head and neck cancer
p53 mutations, 1577

Receptors
androgen
gene mutations, prostate cancer, 277
prostatic hyperplasia and carcinoma, 889
anti-IL-6, antibodies
combined with retinoids, myeloma, 253
anti-Tf, antibodies
combined with retinoids, myeloma, 253
epidermal growth factor
expression, metaplastic bronchial epithelium, 1787
gene amplification, esophageal squamous cell carcinoma, 909
erbB-3
tumor cells expressing, T cell-mediated cytolysis, 1001
erbB-4
tumor cells expressing, T cell-mediated cytolysis, 1001

estrogen
FES-PET and, breast cancer, 933
gene methylation, breast tumors, 805
mRNA levels, breast cancer, 293
status, angiogenesis determination and, 1191
variant and wild-type, ovarian carcinoma, 2029
folate
dietary folate and, neoplastic murine tissue, 1135

Glucocorticoid
prostatic hyperplasia and carcinoma, 889

Hyaluronan
expression, pancreatic cancer cells, 1607

insulin-like growth factor I
regulation by ICI 182780, 2037
interleukin 1
antagonist induction after IL-1 therapy, 501
laminin, M, 67,000
expression, thyroid cancer, 1777
Neu/erbB-2
tumor cells expressing, T-cell-mediated cytolysis, 1001
platelet-derived growth factor β, breast carcinoma, 773
progesterone
gene methylation, breast tumors, 805
9-cis-retinoic acid
combined with cisplatin, human oral squamous carcinoma xenografts, 511
phase I trial, 471
phase I trial, solid tumors, 287
13-cis-retinoic acid
antiproliferative effects, renal cell carcinoma, 1077
high-dose, recurrent malignant glioma treatment, 1931
all-trans-retinoic acid
apoptosis induction, head and neck squamous cell carcinoma cell lines, 855
combined with antireceptor antibodies, myeloma and, 253
retinoic acid, β
expression, renal cell carcinoma, 1077
somatostatin, type 2
gene expression, neuroblastoma, 1757
steroid
prostatic immunohistochemistry, 889
T-cell
β variable region, melanoma after immunotherapy, 767
transforming growth factor β
type II, prostate cancer, 635
transforming growth factor β1
loss of expression, prostate cancer, 1255

TrkA
protein detection by mAb SC3, neuroblastoma, 1361
tumor necrosis factor recombinant human IgG chimera, combined with IL-2, 1341
vascular endothelial growth factor (KDR)
intestinal-type gastric cancer, 1679

Red blood cells
glucose transporter
overexpression, colorectal carcinogenesis, 1151
methotrexate pharmacology, acute lymphocytic leukemia in children, 331

Renal cell carcinoma
local tumor irradiation combined with IL-2 therapy, murine, 1543

Renal cell carcinoma
IL-13 antitumor effects, 1743
MHC class I, LMP, and TAP genes, 1427
13-cis-retinoic acid antiproliferative effects, 1077
retinoic acid receptor β expression, 1077

Renal failure
high-dose melphalan autotransplants, 947

Replication errors
hematological neoplasia, 1583

Resistance: see Drug resistance

Retinoblastoma
gene family expression, lung cancer, 1239
intraocular chemotherapy combined with cyclosporin, 1499
protein alterations, non-small cell lung carcinoma, 1169
Retinoic acid receptor β expression, renal cell carcinoma, 1077
9-cis-Retinoic acid combined with cisplatin antitumor effects, human oral squamous carcinoma xenografts, 511 phase I trial, 471 phase I trial, 287
13-cis-Retinoic acid antiproliferative effects, renal cell carcinoma, 1077 high-dose recurrent malignant glioma treatment, 1931
all-trans-Retinoic acid apoptosis induction, head and neck squamous cell carcinoma cell lines, 855 combined with antireceptor antibodies myeloma and, 253
Retinol plasma levels, cervical intraepithelial neoplasia and cancer, 181
Retroviral gene transfer MDR into peripheral blood progenitor cells, 873 MGMT, human hematopoietic progenitors, 1353
Reverse transcription-polymerase chain reaction MDR1 expression, endometrium, 1981 somatostatin receptor type 2 expression, neuroblastoma, 1757
Rhabdomyosarcoma, colon therapy irinotecan combined with 5-fluorouracil or etoposide, xenograft models, 107
RHAMM expression, pancreatic carcinoma, 1607 Kclin A chain -containing immunotoxin treatment serum fibronectin levels, 1705 RNA breast carcinoma content, 419 TIMP1 expression and adverse prognosis, non-small cell lung cancer, 1369
ST-4 cells thioredoxin, 427 Stem cell factor erythropoiesis stimulation, myelodysplastic syndrome, 1031 Steroids receptors, prostatic immunohistochemistry, 889 Stomach cancer: see Gastric carcinoma Streptozocin combined with carbamustine, refractory melanoma, 1129 resistance MGMT and, brain tumor cell lines, 735 Stromal androgen and glucocorticoid receptors, prostatic hyperplasia and carcinoma, 889 peripherpelial PDGF β receptor, breast carcinoma, 773 Sulindac combined with 5-FU and levamisole, colon carcinoma, 37 Superficial bladder cancer progression p53 mutations and, 1055 Suramin p53 protein induction, 269
Tamoxifen adjuvant therapy node-positive breast cancer, predictors of outcome, 1191 endometrial carcinoma and, 223 high-dose recurrent malignant glioma treatment, 619 -induced apoptosis modulation by HER2 overexpression, MCF-7 cells, 1215 and p53 DNA damage response, 1439 Taxol antiangiogenic activity, 1843 carboplatin pharmacokinetics with, 549 cell motility inhibition, ovarian carcinoma, 1725 T cells CD8+ GM-CSF release, melanoma T-cell epitope detection and, 87 cytotoxic mutant p53-specific, lung cancer cells, 877 epitopes melanoma, detection, 87 leukemia, adult -derived factor, cisplatin resistance, 427 -mediated tumor cell lysis, 1001 peripheral CD3 γ expression, cervical cancer, 1825 receptor-β repertoire, melanoma after immunotherapy, 767 recognition of pml/RAR-α, acute promyelocytic leukemia, 593
signaling deficiency, metastatic melanoma, 1263
tumor-associated
signal transduction defects, ovarian carcinoma, 161
Te: see 3-Ethyl-3'-methyl-
thiattellurcarbocyanine iodide
Tegafur
combined with uracil, phase I and pharmacokinetic study, 1461
Tellurium
-containing cyanine
anticarcinoma activity, mitochondria, 1335
Telomerase
activity, gynecological tumors, 2023
acute myelogenous leukemia activity, 799
bladder cancer activity, 929
lymphage squamous cell carcinoma activity, 1895
Temozolomide
resistance
MGMT and, brain tumor cell lines, 735
Tenascin
antin tenascin 81C6 mAb
intrahecal 111I-labeled, phase I trial therapy, 963
12-O-Tetradecanoylphorbol-13-acetate
growth inhibition, glioblastoma, 1017, 1638
TGF-β2: see Transforming growth factor β2
TGF: See Transforming growth factor
Thioredoxin
cisplatin resistance, 427
Three-dimensional 39P magnetic resonance spectroscopy
hepatic 5-fluorouracil carbosilbism quanimation, 5159
Thrombomodulin
prognostic value, lung cancer, 763
Thymidylate synthase
inhibition
fluoropyrimidine efficacy and, colon 26-B tumors, 1327
inhibitors
AG331, phase I trial, 1685
folate analogues, 227
Thyroid carcinoma
CD44 mRNA isoforms, 1251
c-myc overexpression, 119
M, 67,000 expression, 1777
Tissue
13C-pencolmedine distribution, rats, 541
Tissue inhibitor of metalloproteinase
RNA expression
and adverse prognosis, non-small cell lung cancer, 1369
T lymphocytes: see T cells
TNF-α: see Tumor necrosis factor α
TNM-Gene
cyclin D1 gene amplification, squamous cell carcinoma of esophagus, 1155
α-Tocopherol
plasma levels, cervical intraepithelial neoplasia and cancer, 181
γ-Tocopherol
plasma levels, cervical intraepithelial neoplasia and cancer, 181
Topotecan
phase I trials, 1489
leukemia, 1921
total
AUC curve, limited sampling model, 43
Toxicity: see also Cytotoxicity;
Hematotoxicity; Neurotoxicity
daily subcutaneous low-dose IL-2, 669
high-dose melphalan, multiple myeloma, 947
Toxins: see Immunotoxins; Oncotoxins
Transferrin
anti-Tf receptor antibodies
combined with retinoids, myeloma and, 253
and resistance to gallium nitrate, lymphoid leukemic cells, 1009
Transforming growth factor β
receptor type II, prostate cancer, 635
Transforming growth factor β1
receptors
loss of expression, prostate cancer, 1255
Transforming growth factor β2
secretion
stimulation by TNF-α, MCF-7 cells, 827
Transitional cell carcinoma
recurrence
detection, clonality and, 1795
Transitional cell carcinoma, bladder
multifocal
molecular screening with p53 mutations, 1795
progression
p53 mutations and, 1055
Transplantation, liver
cyclosporin A chemosensitization, post-liver transplant patient plasma, 531
Transplants
autotransplants
high-dose melphalan, renal failure, 947
Transporters associated with antigen processing
gene expression
MHC class I and, renal cell carcinoma, 1427
Trisomy 7
prognostic significance, prostate cancer, 1553
Trisomy 12
chromosome 13q14 deletions and, B-cell chronic lymphocytic leukemia, 1673
TrkA protein
detection by mAb SC3, neuroblastoma, 1361
Trophoblastic tumors
placental site
molecular analysis and clinical experience, 897
Tumor antigen genes
expression, gastric carcinoma, 1619
Tumor-associated lymphocytes
signal transduction defects, ovarian carcinoma, 161
Tumor blood vessels
counts, intestinal-type gastric cancer, 1679
eosinophil peroxidase, ovarian and endometrial cancers, 1867
Tumor cell proliferation
cytotoxic therapy, head and neck tumors, 1453
prognostic significance, breast carcinoma, 147
Tumor cells
chemosensitivity
enhancement by gene therapy, 1089
death
apoptotic, and chemosensitivity, 623
HSV-TK DNA and ganciclovir, 47
lymphocytes, 785
gene modification
active immunotherapy, breast and ovarian cancer, 59
growth suppression by truncated p21 adenovirus, 1221
lysis
T-cell-mediated, 1001
multidrug-resistant
vulnerability to aromatic fatty acids, 865
Tumor colony-forming units
PIXY321 effects, 1713
Tumor markers
eosinophil peroxidase, ovarian and endometrial cancers, 1867
serum
half-life, germ cell tumors, 1565
Tumor necrosis factor
receptors
recombinant human IgG chimera.
combined with IL-2, 1341
Tumor necrosis factor α
stimulation of TGF-β, secretion, MCF-7 cells, 827
TNF-B1(Fv) fusion protein, cytotoxic and antitumor activity, 1523
Tumor promoters
phorbol ester
growth inhibition, glioblastoma, 1017, 1638
Tumors
13C-pencolmedine distribution, rats, 541
folate receptor expression
dietary folate and, murine, 1135
growth suppression by IL-10, melanoma, 1969
growth suppression by truncated p21 adenovirus, 1221
somatostatin receptor type 2 expression, 1757
TNF-B1(Fv) fusion protein antitumor activity, 1523
Tumors, bladder
doxorubicin pharmacodynamics, 1275
Tumors, brain
methylator resistance
MGMT and, 735
resection cavities with subarachnoid communication
intrahecal 111I-labeled 81C6 mAb therapy, phase I trial, 963
Tumors, breast
ER and PR gene methylation, 805
Tumors, colon
fluoropyrimidine efficacy and thymidylate synthase inhibition, 1327
Tumors, colorectal
Clinical Cancer Research 2071
apoptosis, 1999
Tumors, endometrial
sporadic
DNA mismatch repair genes, 1907
Tumors, germ cell
metastatic nonseminomatous
serum tumor marker half-life, 1565
Tumors, gynecological
telomerase activity, 2023
Tumors, head and neck
cytotoxic therapy
tumor cell proliferation, 1453
Tumors, hematological
replication errors, 1583
Tumors, leptomeningeal
intrathecal 125I-labeled 81C6 mAb
treatment, phase I trial, 963
Tumors, liver
regional chemotherapy
chemosensitivity-directed, prospective
decision-aiding trial, 1469
Tumors, lung
cathepsins, 561
malignant
inhaled nIL-2, phase I trial, 1115
downstream analogue-induced cell death, 441
Tumors, mesenchymal
Mel-CAM immunoreactivity, 569
Tumors, solid
breast
batimastat growth inhibition, mice, 1207
omega-3 fatty acid suppressive
effects, 1751
9-cis retinoic acid, phase I trial, 287
Tumors, trophoblastic
placental site
molecular analysis and clinical experience, 897
Tumor suppressor genes: see also Genes
DCC
loss of expression, disseminated
neuroblastoma, 1097
p16
expression, breast cancer, 1993
p19
expression, breast cancer, 1993
p53
deduced mutant CTL target, lung
cancer cells, 877
human papilloma virus and, head and
neck cancer, 755
mutations, bladder cancer, 1055
mutations, p21 expression and, 1571
mutations, recurring head and neck
cancer, 1577
point mutations, colorectal carcinoma, 1049
Tyrosine kinase
inhibition by quercetin, phase I clinical
trial, 659

U
U-7779: see Bizelesin
U-80244: see Carzelesin
UCN-01: see 7-Hydroxystaurosporine
UFT
phase I and pharmacokinetic study, 1461
Urcael
combined with tegafur, phase I and
pharmacokinetic study, 1461
Urine
irinotecan metabolites, 1943
pyrimidine levels, 1937
Urokinase plasminogen activator
prognostic significance, breast cancer, 613

V
Vaccines
BEC2 anti-idiotypic
immunization, melanoma, 679
Newcastle disease virus-infected
autologous tumor cell
active specific immunotherapy,
colorectal carcinoma, 21
Vascular endothelial growth factor
intestinal-type gastric cancer, 1679
mRNA expression, lung cancer, 1411
receptor (KDR)
intestinal-type gastric cancer, 1679
serum levels, 821
Vascularity
proliferative breast disease and
carcinoma in situ, 1873
Vascular leak syndrome
serum fibronectin levels and,
immunotherapy, 1705
Vasopressin
and intraperitoneal drug
pharmacokinetics, 311
Vessel counts
intestinal-type gastric cancer, 1679
Vimentin
MB-1 tumor cell proliferation rate,
breast carcinoma, 147

Viruses
human papilloma
and p53, head and neck cancer, 755

W
White blood cells
peripheral
dacarbazine-induced DNA damage,
malignant melanoma, 303
Whole blood
Pgp inhibition, flow cytometric assay, 7
Wild-type estrogen receptor
ovarian carcinoma, 2029
Wild-type p53
cytotoxicity potentiation, colon cancer, 1649
dominance, colon carcinoma cells, 1639
gene expression
adenoviral-mediated, radiation
sensitization, 1665

X
Xenografts
colon adenocarcinoma or
rhabdomyosarcoma
irinotecan combined with 5-
fluouracil or etoposide, 107
colon carcinoma
5'-AdThd modulation of IdUrd
metabolism, 981
hepatocellular carcinoma
multidrug resistance, murine model, 695
MRP-mediated multidrug resistance
PAK-104P reversal, 369
oral squamous carcinoma
antitumor effects of cisplatin
combined with ALR1057, 511
prostatic carcinoma
LuCaP 23, characterization, 1039

Y
\^Y-CYT-356
hormone-refractory prostate cancer
treatment, 1289
Instructions for Authors

Scope

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genetics; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Femeny-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Manuscript Submission

Submit papers directly to one of the six Senior Editors, each of whom is responsible for a particular area of research. Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

Figure

Provide four original sets of figures (whether line-cut drawings or halftones). Each set should be in separate labeled envelopes, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating the top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity. Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. In 1996, the cost of color reproduction charged to authors will be $975 per color figure. Submit color figures on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors' corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief and Senior Editors

John Mendelsohn, M.D.
Department of Educational Publishing Services–227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Telephone: 713-792-6014
Fax: 713-792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Cell proliferation and death—preclinical, and clinical trials; radiation therapy, surgery, and subspecialty investigation

Waun Ki Hong, M.D.
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Telephone: 713-792-6363
Fax: 713-796-8655
E-mail: waun.hong@isqm.mda.uh.tmc.edu

Clinical trials targeted at specific malignancies; chemoprevention

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Telephone: 301-496-3185
Fax: 301-402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Telephone: 410-550-5153
Fax: 410-614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K9/448
600 Highland Avenue
Madison, WI 53792
Telephone: 608-263-9069
Fax: 608-263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

David R. Spriggs, M.D.
Developmental Chemotherapy Service
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Telephone: 212-639-2203
Fax: 212-717-3272
E-mail: dspriggs@pop.ski.mskcc.org

Preclinical pharmacology, pharmacological clinical trials

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Telephone: 301-402-2023
Fax: 301-402-2040
E-mail: jntrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Educational Publishing Services–227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, Telephone 713-792-6014, Fax 713-792-6016 or:
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Co-Sponsored by the Joint Section on Tumors of the American Association of Neurological Surgeons and Congress of Neurological Surgeons

Cancer of the Central Nervous System

June 7-11, 1997
Loews Coronado Bay Resort
San Diego, CA

CONFERENCE CO-CHAIRPERSONS

Webster K. Cavenee / La Jolla, CA
Peter McL. Black / Boston, MA

PROGRAM COMMITTEE

William F. Chandler / Ann Arbor, MI
Joseph Piepmeier / New Haven, CT
Jean Y. J. Wang / La Jolla, CA

Keynote Address
Charles B. Wilson / San Francisco, CA

Triumphs and Challenges of Present Diagnosis and Management
Catherine Dumas-Duport / Paris, France
Peter McL. Black / Boston, MA
Jay S. Loeffler / Boston, MA
Victor A. Levin / Houston, TX

Neurobiology and Developmental Biology
Fred H. Gage / La Jolla, CA
Mark D. Noble / Salt Lake City, UT

Genetic Predispositions to CNS Tumors
Jean Y. J. Wang / La Jolla, CA
Lawrence A. Donehower / Houston, TX
Eric C. Holland / Bethesda, MD

Molecular Genetics
David N. Louis / Boston, MA
Huel-Jen Su Huang / La Jolla, CA
Otmar D. Wiestler / Bonn, Germany

New Targets for Therapy
Mark L. Rosenblum / Detroit, MI
David Hockenberry / Seattle, WA
Jerry W. Shay / Dallas, TX

Receptor Mediated Growth Control
Charles D. Stiles / Boston, MA
Webster K. Cavenee / La Jolla, CA
Lewis T. Williams / San Francisco, CA

Novel Therapies
Xandra O. Breakefield / Boston, MA
Jackson B. Gibbs / West Point, PA
Judah Folkman / Boston, MA
Frank McCormick / San Francisco, CA

ADDITIONAL SPEAKERS TO BE ANNOUNCED

Application Deadline: March 14, 1997

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aacr.org
Website: http://www.aacr.org
Hit our Home Page on the World Wide Web!

http://www.aacr.org

Our web site features . . .

- **AACR scientific meeting schedule**
- **Table of Contents of AACR journals**
- **Instructions for Authors**
- **Information about AACR Research Fellowships and Travel Awards**

*Plus . . . The latest AACR newsletter, and much more!*
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 11,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the unchallenged funding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration at presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focused meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of over 11,500 member researchers in the cancer field;
10. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application:
January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>in AACR Office</td>
<td></td>
</tr>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aacc.org

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1997 annual dues for active members are $175, $100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($90 in 1997) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ___________________________ DATE OF BIRTH: ____________

LAST FIRST M.I.

PRESENT POSITION/TITLE: ___________________________

INSTITUTIONAL AFFILIATION: ___________________________

INSTITUTIONAL ADDRESS: ___________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ___________________________

E-MAIL NUMBER (CARRIER): ___________________________

FAX NUMBER: ___________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

_____ Biochemistry and Biophysics
_____ Biostatistics
_____ Carcinogenesis
_____ Cellular Biology and Genetics
_____ Clinical Investigations
_____ Endocrinology
_____ Epidemiology
_____ Immunology
_____ Molecular Biology and Genetics
_____ Preclinical Pharmacology and Experimental Therapeutics
_____ Virology
_____ Other: ___________________________ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

CANDIDATE IS APPLYING FOR (Check one): ☐ ACTIVE ☐ CORRESPONDING MEMBERSHIP

CANDIDATE NOMINATED BY*: ___________________________

(SECOND BY*: ___________________________

(Please print) (Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

__________________________________________ (Signature of Nominator*)

__________________________________________ (Date)

__________________________________________ (Signature of Seconder*)

__________________________________________ (Date)

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. substantially reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
9. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1996 are $35 for associate members residing in the Americas and $45 for residents of other countries. For 1997 these rates are $45 and $55, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. For 1997 these rates are $45 and $55, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1996 for the forthcoming annual meeting must have paid dues for 1996. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1996 may retain associate membership until December 31, 2000. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ___________________________________________ DATE OF BIRTH: ____________

LAST FIRST M.I. 

INSTITUTIONAL AFFILIATION: ________________________________________________________________

INSTITUTIONAL ADDRESS: ________________________________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ______________________ FAX NUMBER: ______________________

PRESENT ACADEMIC STATUS/TITLE (Please check only): ____________________________

- Graduate Student 
- Medical Student 
- Physician in Training 
- Postdoctoral Fellow 

PRIMAR Y FIELD OF RESEARCH (Please check only one):

- Biochemistry and Biophysics 
- Biostatistics 
- Carcinogenesis 
- Clinical Investigations 
- Endocrinology 
- Epidemiology 
- Immunology 
- Molecular Biology and Genetics 
- Other: ____________________________ (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

____________________________________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

____________________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

CANDIDATE NOMINATED BY*: _______________________________________________________

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ___________________________________________ Date: _____________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ___________________________________________ Date: ____________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1996, dues are $35 for associate members residing in the Americas and $45 for residents of other countries. For 1997, these rates will be $45 and $55, respectively.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:
The enclosed dues payment should be applied to the □ current □ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- MacWrite
- Microsoft Word (DOS, Windows, and Macintosh)
- WordPerfect (DOS, Windows, and Macintosh)
- XyWrite (DOS and Windows)

Also acceptable:

- Ability
- AmiPro
- A_\textit{S} TeX
- Appleworks
- ArborTeX
- ArborText
- ClarisWorks WP
- CPT 8000
- CTOS
- Diablo
- DisplayWrite
- Duet
- Einstein
- Enable
- EXP
- Final Word
- FullWrite
- GemWord Plus
- IBM Writing Assistant
- Interleave
- Latex
- Leading Edge
- Lotus Manuscript
- Lotus Write
- Mass 11
- MS Works
- MS Works WP Mac
- Multimate
- Multimate Advantage
- Nibia
- Nisus (to ASCII file)
- Notewriter
- Obun
- OfficeWriter
- PC Write
- PFS First Choice
- Professional Write
- Q&A Write
- Quark XPress
- RagTime MS Works
- Rich Text Format
- RSG (to ASCII file)
- Signature
- SLiTEX
- SmartWhere
- SmartWrite II
- SoloWriter
- Sprint
- Stx
- SunWrite
- Symphony
- TextEXecutive
- Textures
- Total Word
- Troff
- \textmu TeX
- Volkswriter
- VuWriter
- Wang OIS
- Wang WPS
- Windows Writer
- Window Works
- Windows Write
- WiziWord
- Wordstar
- Wordstar 2000
- WriteNow
- Xerox

Software packages that we are unable to translate:

- FrameMaker
- PageMaker
- Ready, Set, Go
- Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ____________________________
Name of computer used (e.g., IBM/PS2): ____________________________
Operating system and version (e.g., DOS 3.3): ____________________________
Word processing program and version (e.g., WordPerfect 5.0): ____________________________
  [See reverse for acceptable programs.]

Manuscript number: ____________________________________________
First author: ____________________________________________________
Corresponding author (if different from first author): ____________________________
Telephone/FAX numbers: ____________________________________________

This form (both sides) may be reproduced.
Clinical and translational investigations continue to have a dramatic impact on the treatment of cancer, making the need for up-to-date information increasingly important. Every month, basic and clinical cancer researchers turn to *Clinical Cancer Research* for the latest reports of significant new studies. Act now to ensure you receive research findings that are too important to miss.

**SUBSCRIBE TODAY** Call 1-800-875-2997 or 201-627-2427 or mail back the coupon below.

**ORDER FORM**

☑ Yes! I'd like to subscribe!

**Clinical Cancer Research**

Vol. 3, 1997, 12 issues, ISSN 1078-0432

**Institutional** (Available only as a combined subscription with Cancer Research)

☑ $685

☑ $130 should be added for delivery outside the U.S.

**Individual**

☑ $105 non-member

☑ $40 should be added for delivery outside the U.S.

AACR members: Contact the AACR for rates, (215) 440-9300.

**Canada:** Add 7% GST. **MD:** Add state sales tax.

**Individual subscriber:** I certify that this subscription is solely for my personal use and will not be used in a library.

Method of Payment

☑ Enclosed check or money order in U.S. dollars drawn on U.S. bank, Payable to American Association for Cancer Research.

☑ Institutional purchase order # is enclosed.

☑ Please charge my ☐ MasterCard ☐ VISA ☐ American Express

Account Name

Account No.

Expiration Date

Signature

☑ Please send me *Instructions for Authors*.

Mail coupon to: *Clinical Cancer Research*, P.O. Box 3000, Denville, NJ 07834-9359. Those paying by credit card can fax to: (215) 440-9354.
1997 RESEARCH FELLOWSHIPS

For Young Scientists at the Postdoctoral or Clinical Fellow Level

- **1997 Research Fellowship in Clinical/Translational Research:** This Fellowship, sponsored by Amgen, Inc., will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious clinical or translational cancer research.

- **1997 Research Fellowship in Clinical Research:** This Fellowship, sponsored by Bristol-Myers Squibb Oncology, will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious clinical cancer research.

- **1997 Research Fellowship in Prevention Research:** This Fellowship, sponsored by the Cancer Research Foundation of America, will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious cancer prevention research.

- **1997 Research Fellowships in Basic Research:** Three Fellowships, sponsored by The Sidney Kimmel Foundation for Cancer Research, Hoechst Marion Roussel, and the AACR, will each provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious basic cancer research.

- The winners of the Research Fellowships will be announced at the AACR Annual Meeting in San Diego, CA, in April 1997.

**Eligibility**

Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Academic faculty holding the rank of assistant professor or higher, graduate or medical students, government employees, and employees of private industry are not eligible. A candidate need not be a member of the AACR at the time of application, but he or she must be nominated by an AACR Member. Associate Members may not be nominators.

**Selection Process**

Applications will receive careful scientific evaluation by a prestigious, multidisciplinary Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Applications must be submitted in complete form by **February 14, 1997**.

**For Further Information/Application Forms**

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
e-mail: aacr@aacr.org
PLENARY SESSION
Genetic Predisposition to Cancer (Louise C. Strong)

SYMPOSIA
Genes, Cell Proliferation, and Antineoplastic Drugs (George F. Vande Woude)
Diagnostic, Prognostic, and Therapeutic Aspects of Tumor Suppressor Genes (David Sidransky)
Cell Cycle Regulation (Peggy J. Farnham)
Breast Cancer Genes (Barbara L. Weber)
Metastasis, Adhesion, and Angiogenesis: Mechanisms and Therapeutic Strategies (Marilyn M. Cornwell and Elise C. Kohn)
Novel Clinical Trials Based on Genetics and Molecular Therapeutics (Stephen H. Friend)
Apoptosis and Cancer Chemotherapy (Michael B. Kastan)
Identification and Management of Genetic-High-Risk Individuals (Albert de la Chapelle)
Demystifying the Role of Cytokines in Tumor Immunobiology: Status and Future Utility (Michael A. Caligiuri)
Telomerase and Clinical Applications (Titia de Lange)
Acute Myelocytic Leukemia (Clara Derber Bloomfield)
Prostate Cancer (Donald S. Coffey)
Colon Cancer (Margaret A. Tempero)
Signaling Pathways for Novel Therapeutics (Anthony J. Pawson)
Animal Models for Functional Analysis of Tumor Suppressor Genes (Terry A. Van Dyke)
New Techniques for Molecular Diagnostics (Eric S. Lander)
Mechanisms of Cellular Senescence (J. Carl Barrett)
Damage Response Pathways (Philip C. Hanawalt)
Gene Interactions with the Environment/Carcinogenesis (Allan Balmain)
Epidemiology and Pathogenesis of Secondary Cancers (Frederick P. Li)

CONTROVERSY SESSIONS
What Are the Appropriate Therapeutic Uses of Hematopoietic Growth Factors? (Peter J. Quesenberry)
Estrogen Replacement Therapy: Beneficial or Harmful? (Larry Norton)
What is the Value of Mammography in Young and Genetically Susceptible Women?
Is the Time Right for Cancer Chemoprevention? (Edward Bresnick)
Gene Patents: Help or Hindrance to Conquering Cancer?
What is the Role of Prophylactic Surgery in Breast and Ovarian Cancer? (Samuel A. Wells, Jr.)
What Are the Appropriate Guidelines for the Use of Archived Human Tissue?

How Robust Are Antisense/Third Strand Techniques for Gene Disruption?

“MEET-THE-EXPERT” SUNRISE SESSIONS
Angiogenesis
Gene Therapy (Jack A. Roth)
Strategies for Drug Development (Daniel D. Von Hoff)
Advances in Our Molecular Understanding of Lymphoproliferative Disease (A. Thomas Look)
FHIT Gene (Kay Huebner)
Cancer Vaccines (David P. Carbone)
Lung Cancer
Costimulatory Molecules in Tumor Immunity
New Approaches to Overcoming Multidrug Resistance (Alan F. List)
Advances in Oncologic Imaging (Michael J. Welch)
Retinoids and Cancer Prevention (Waan Ki Hong)
Mechanisms of Regulation of p53 Function (Guillermina Lozano)
Cell Cycle Control of Genetic Stability (Geoffrey Wahl)
Farnesyl Transferase Inhibitors (Allen I. Oliff)
Bioinformatics/Genomics
DNA Methylation in Cancer (Stephen B. Baylin)
Chemoprevention in Transgenic Animals (James M. Phang)
Advances in Stem Cell Transplantation
Psychosocial Issues in Cancer
Advances in the Management of AIDS-related Malignancies (Ellen G. Feigal)
Recent Developments in Our Understanding of Minimal Residual Disease (John G. Gribben)
Ovarian Cancer Update (Robert C. Bast, Jr.)
The Biological Basis of the New International Classification of Lymphoma (Elaine S. Jaffe)
Recent Developments in Radiotherapy
Colon Cancer Genes
Extracellular Connections
Barrett’s Esophageal Cancer and Tumor Progression Models (Brian J. Reid)
H. Pylori
Transcriptional Models and Drug Discovery (William G. Kaelin)

METHODS WORKSHOPS AND EDUCATIONAL SESSIONS
To be announced

Abstract Deadline: November 12, 1996

Further Information: AACR Office · Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483 · TELEPHONE: (215) 440-9300 · FAX: (215) 440-9313 · Email: aacr@aacr.org · For up-to-date information visit the AACR Website at http://www.aacr.org
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Basic and Clinical Aspects of Breast Cancer

March 7-12, 1997
The Keystone Resort, Keystone, Colorado

CONFERENCE CHAIRPERSONS
J. Carl Barrett / Research Triangle Park, NC
Karen S.H. Antman / New York, NY
Mary-Claire King / Seattle, WA

SCIENTIFIC PROGRAM

Keynote Addresses
Mary-Claire King / Seattle, WA
Karen S.H. Antman / New York, NY

Basic Biology of the Breast
José Russo / Philadelphia, PA
Marc E. Lippman / Washington, D.C.
C. Kent Osborne / San Antonio, TX

Molecular and Cellular Aspects of Breast Cancer
Jerry W. Shay / Dallas, TX
Mina J. Bissell / Berkeley, CA
Martha R. Stamper / Berkeley, CA

Genetic Predisposition to Breast Cancer
David E. Goldey / Lyon, France
P. Andrew Futreal / Durham, NC

Mechanisms of Hormone Action
V. Craig Jordan / Chicago, IL
Myles A. Brown / Boston, MA
Kenneth S. Korach / Research Triangle Park, NC

BRCA1 and BRCA2 Function/Biochemistry
Roy A. Jensen / Nashville, TN
Wen-Hwa Lee / San Antonio, TX
David M. Livingstone / Boston, MA
Frank J. Calzone / Thousand Oaks, CA

Experimental Models of Breast Cancer
Tak W. Mak / Toronto, Ontario, Canada
Michael N. Gould / Madison, WI

Epidemiology of Breast Cancer
Walter C. Willett / Boston, MA
Maureen Henderson / Seattle, WA
Malcolm C. Pike / Los Angeles, CA
Mary S. Wolff / New York, NY

Clinical Aspects of Breast Cancer
Judy E. Garber / Boston, MA
Jeffrey T. Holt / Nashville, TN
M. John Kennedy / Baltimore, MD

Applicants are encouraged to submit abstracts for poster presentation.
Application deadline: January 3, 1997

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
aacr@aacr.org (E-mail)
http://www.aacr.org